<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chronic functional constipation and fecal incontinence in infants, children, and adolescents: Treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chronic functional constipation and fecal incontinence in infants, children, and adolescents: Treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chronic functional constipation and fecal incontinence in infants, children, and adolescents: Treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Manu R Sood, MBBS, FRCPCH, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            B UK Li, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Constipation is common among children, affecting up to 30 percent of children [
         <a href="#rid1">
          1-3
         </a>
         ], and the vast majority of chronic constipation is functional [
         <a href="#rid4">
          4
         </a>
         ]. The approach to treatment of functional constipation depends on the child's age, presence of underlying behavioral or dietary triggers, and chronicity of the symptoms.
        </p>
        <p>
         The treatment of chronic functional constipation and fecal incontinence in infants and children will be discussed here. Related material is presented in the following topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5906.html" rel="external">
          "Constipation in infants and children: Evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99538.html" rel="external">
          "Functional constipation in infants, children, and adolescents: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5859.html" rel="external">
          "Functional fecal incontinence in infants and children: Definition, clinical manifestations, and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5872.html" rel="external">
          "Recent-onset constipation in infants and children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1757006275">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Functional constipation
         </strong>
         – Functional constipation is defined by criteria that include infrequent, hard, and/or large stools; fecal incontinence; painful defecation; or volitional stool retention, if these symptoms are not explained by another medical condition, as outlined by the Rome IV consensus  (
         <a class="graphic graphic_table graphicRef57882" href="/z/d/graphic/57882.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid5">
          5,6
         </a>
         ]. Although abdominal pain is often associated with functional constipation, it is not among the diagnostic criteria. (See
         <a class="medical medical_review" href="/z/d/html/99538.html" rel="external">
          "Functional constipation in infants, children, and adolescents: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Functional fecal incontinence
         </strong>
         – Functional fecal incontinence is the repeated involuntary passage of stool in the underwear after the acquisition of toileting skills (typically after four years of age), in the absence of overt neuromuscular anorectal dysfunction. This term is preferred rather than encopresis or soiling. It is classified as "retentive" if it is associated with functional constipation and "nonretentive" if it occurs in the absence of symptoms and signs of functional constipation [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5859.html" rel="external">
          "Functional fecal incontinence in infants and children: Definition, clinical manifestations, and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fecal impaction
         </strong>
         – This term is used to describe markedly increased amounts of stool in the rectum and colon. It is a subjective judgement based on clinical findings, such as a large stool mass noted on physical examination and/or radiograph (if performed), especially in association with a history of passing infrequent and large-caliber stools. (See
         <a class="local">
          'Disimpaction (for select children)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TREATMENT OF CONSTIPATION IN INFANTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Constipation is evaluated and treated somewhat differently in infants than in children. When constipation presents early in life, organic disease (eg, cystic fibrosis, Hirschsprung disease), an anorectal malformation, and, especially, anal stenosis must be considered [
         <a href="#rid7">
          7
         </a>
         ]. The organic causes of constipation in infants are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5906.html" rel="external">
          "Constipation in infants and children: Evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99538.html" rel="external">
          "Functional constipation in infants, children, and adolescents: Clinical features and diagnosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3964671159">
         <span class="h2">
          Initial measures (nonpharmacologic)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants with functional constipation frequently respond to treatment with nondigestible osmotically active carbohydrates, such as sorbitol-containing juices (eg, apple, prune, or pear). Although dark corn syrup was previously used, we no longer suggest it, because not all preparations contain osmotically active carbohydrates.
        </p>
        <p class="headingAnchor" id="H919686957">
         <span class="h2">
          Pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If these measures are unsuccessful, addition of osmotic laxatives and/or occasional disimpaction with
         <a class="drug drug_pediatric" data-topicid="13337" href="/z/d/drug information/13337.html" rel="external">
          glycerin
         </a>
         suppositories can be useful. Appropriate choices for infants include the following (all are off-label uses for this age group):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lactulose
         </strong>
         <strong>
          or
         </strong>
         <strong>
          sorbitol
         </strong>
         – These are frequently used and are usually effective in infants. A typical dose for either
         <a class="drug drug_pediatric" data-topicid="13405" href="/z/d/drug information/13405.html" rel="external">
          lactulose
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12801" href="/z/d/drug information/12801.html" rel="external">
          sorbitol
         </a>
         is 1 mL/kg, once or twice daily  (
         <a class="graphic graphic_table graphicRef63381" href="/z/d/graphic/63381.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polyethylene glycol 3350
         </strong>
         – Experience with
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         (or Miralax) is increasing in infants, although the safety is less well established than with older age groups. The use of this laxative for infants and toddlers &lt;24 months of age was reported in several case series [
         <a href="#rid8">
          8-10
         </a>
         ]. In addition, a randomized trial that compared polyethylene glycol with and without electrolytes in children included a few subjects between 6 and 24 months of age [
         <a href="#rid11">
          11
         </a>
         ]. The treatment was generally effective, and no adverse effects were noted in these studies. The mean effective maintenance dose was approximately 0.8 g/kg body weight per day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycerin
         </strong>
         <strong>
          suppositories
         </strong>
         – Occasional disimpaction with
         <a class="drug drug_pediatric" data-topicid="13337" href="/z/d/drug information/13337.html" rel="external">
          glycerin
         </a>
         suppositories can be useful. However, these should be used with caution because they can cause rectal and anal irritation and may lead to chronic symptoms. (See
         <a class="local">
          'Details on medications'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5872.html" rel="external">
          "Recent-onset constipation in infants and children", section on 'Infants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For infants who do not respond to osmotic laxatives,
         <a class="drug drug_pediatric" data-topicid="12786" href="/z/d/drug information/12786.html" rel="external">
          senna
         </a>
         may be tried short-term (eg, by giving 1 to 2.5 mL daily of syrup with 8.8 mg sennosides per 5 mL for up to three months) [
         <a href="#rid12">
          12
         </a>
         ]. However, this has not been well studied in this age group and is an off-label use. Senna may cause perianal skin breakdown and blistering if the stool is left in contact with the skin for a prolonged time and/or if high doses are given.
        </p>
        <p>
        </p>
        <p>
         The following drugs are
         <strong>
          not recommended
         </strong>
         for infants:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mineral oil – Oral administration of
         <a class="drug drug_pediatric" data-topicid="12614" href="/z/d/drug information/12614.html" rel="external">
          mineral oil
         </a>
         is not recommended for infants, because of potential risks of pneumonitis if aspirated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enemas – Potential complications in this age group, such as hyperphosphatemia (which could be life-threatening), hypocalcemia, or perforation. Occasionally, pure saline enemas (with no phosphate) may be used for infants but only when necessary and under close medical supervision.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bisacodyl –
         <a class="drug drug_pediatric" data-topicid="13080" href="/z/d/drug information/13080.html" rel="external">
          Bisacodyl
         </a>
         tablets are enteric coated and are therefore ineffective when crushed, so there is no preparation appropriate for infants.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          TREATMENT OF CONSTIPATION IN CHILDREN
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          General approach and goals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of chronic functional constipation and fecal incontinence is based on the concept that chronic constipation causes the colon to be unresponsive to stool burden due to distension and that effective treatment requires consistent and complete emptying of the colon, so that it becomes conditioned to work on its own. This concept is known as "bowel retraining" [
         <a href="#rid7">
          7,13-18
         </a>
         ]. There are four general steps in bowel retraining:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disimpaction (for children with a large rectal stool mass or fecal incontinence)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolonged laxative treatment and behavioral therapy to achieve regular evacuation and avoid recurrent constipation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietary changes (primarily increasing fiber and fluid content) to maintain soft stools
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gradual tapering and withdrawal of laxatives as tolerated
        </p>
        <p>
        </p>
        <p>
         This multimodal therapy is particularly helpful for children who have gone several days between bowel movements, have an anal fissure with pain or bleeding, or have very large-diameter stools with marked straining. The type and intensity of the intervention should be tailored to the severity of constipation and the child's developmental stage, and close follow-up is often necessary.
        </p>
        <p>
         The goal of therapy is the passage of soft stools, ideally once per day and no less than every other day. This goal of frequent defecation is important to overcome constipation, although less frequent defecation patterns are common and acceptable in children without a history of constipation. Weeks to months and sometimes years of laxative and behavioral therapy may be necessary before this goal is achieved. The child's parents or caregivers must be effectively educated about bowel retraining and behavior modification, so that they can carry out the sustained treatment at home. Ultimately, the symptoms improve in most patients. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
         The combined laxative and behavioral approach is supported by a systematic review of randomized and quasi-randomized trials that concluded that combination therapy was more effective than laxative therapy alone [
         <a href="#rid18">
          18
         </a>
         ]. It is also supported by observational studies and clinical experience [
         <a href="#rid19">
          19-26
         </a>
         ]. Analysis of intervention trials is complicated by the varied methods used for laxative and behavioral treatments. Consequently, conclusions also vary but generally support the use of combination therapy that incorporates both of these modalities.
        </p>
        <p>
         The following tables summarize a typical treatment plan for children with chronic constipation (details are provided in the remainder of this topic review):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with chronic constipation and fecal incontinence  (
         <a class="graphic graphic_table graphicRef54749" href="/z/d/graphic/54749.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with chronic constipation but without overflow fecal incontinence  (
         <a class="graphic graphic_table graphicRef61175" href="/z/d/graphic/61175.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Parental education
         </span>
         <span class="headingEndMark">
          —
         </span>
         Effective education of the parents/caregivers and the child with regard to constipation is crucial in changing chronic behavior patterns [
         <a href="#rid7">
          7,27
         </a>
         ]. Regular follow-up and ongoing support and encouragement during periodic office visits or phone conversations are essential.
        </p>
        <p>
         Key messages for education are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Remove negative attributions
         </strong>
         – The parent or caregiver must understand that fecal incontinence due to overflow does not constitute willful and defiant behavior by the child but actually represents physiologic loss of continence. The child should therefore not be scolded or otherwise punished for episodes of incontinence [
         <a href="#rid28">
          28,29
         </a>
         ]. In toddlers with constipation, toilet training should be postponed since it will prove unsuccessful until rectal awareness is restored and defecation is pain-free [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/99538.html" rel="external">
          "Functional constipation in infants, children, and adolescents: Clinical features and diagnosis", section on 'Contributing factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Understand the cyclic nature of constipation and how to reverse this
         </strong>
         – The clinician should explain the behavioral and physiologic contributors to constipation in easy-to-understand lay language, with descriptions of how and why the constipation became chronic, how constipation can cause fecal incontinence, and the concept of bowel retraining. A diagram to support this explanation, with key points in lay language, is shown in the figure, which can be printed and given to the family to support the verbal explanations  (
         <a class="graphic graphic_figure graphicRef74718" href="/z/d/graphic/74718.html" rel="external">
          figure 1
         </a>
         ). Other education for children and their families is provided in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DSgBj7Mc_4sc&amp;token=3BBziCZQDrEhIlt93szQloH6eZnp6PMXkxC7JnVMP%2FXKyr3EQzKi3Llc7zzUgmOzqhQmI7%2BqBhijA5%2F5ijf7nA%3D%3D&amp;TOPIC_ID=5873" target="_blank">
          this video
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Both behavioral interventions and laxatives are important parts of treatment
         </strong>
         – Education should emphasize the role of behavioral contributors to functional constipation, especially the vicious cycle of pain/fear and stool withholding, and that behavioral interventions are geared toward reversing this cycle. This is particularly important for younger children who develop constipation around the time of toilet training. In addition, it is important to explain the need for laxatives and the safety of the type of laxative that will be prescribed to allay any concerns about the safety of long-term laxative use. (See
         <a class="local">
          'Stepwise approach to bowel retraining'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recovery will be gradual
         </strong>
         – Parents or caregivers should be advised that the process of bowel retraining, with readjustment of the nerves and muscles in the rectum, can take as long as six months to several years. Most children experience improvement with appropriate treatment, but relapses or chronic symptoms are common. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         In severe cases, the parents and/or clinician may need to enlist the help of the school and teacher. Some children may benefit from access to a private bathroom. The teacher should be sensitive to the child's problem, permitting use of the bathroom whenever requested (perhaps using a prearranged, unobtrusive signal to avoid drawing attention). In addition, it may be helpful to have a change of clothing available in case an episode of fecal incontinence occurs.
        </p>
        <p class="headingAnchor" id="H859713080">
         <span class="h2">
          Stepwise approach to bowel retraining
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Disimpaction (for select children)
         </span>
         <span class="headingEndMark">
          —
         </span>
         "Fecal impaction" is a term used to describe markedly increased amounts of stool in the rectum and colon, which is a subjective judgement based on clinical findings.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – The majority of children who come to medical attention because of chronic constipation have fecal impaction and will benefit from a regimen to disimpact the rectum before beginning maintenance therapy [
         <a href="#rid7">
          7,27,31
         </a>
         ]. This step is sometimes described as a "clean out" in discussions with patients and their families. We suggest a disimpaction step for children with any of the following characteristics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Constipation-associated fecal incontinence
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Significant stool mass palpable on abdominal or digital rectal examination or on abdominal radiograph (if performed)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of incomplete or infrequent evacuation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of regimen
         </strong>
         – Disimpaction and catharsis can be effectively accomplished with oral or nasogastric medications, rectal medications, or a combination. The parents/caregivers and child should be involved in the decision regarding the appropriate route [
         <a href="#rid32">
          32
         </a>
         ]. Considerations are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most children, we suggest an oral regimen for disimpaction because this method is noninvasive and may help the child feel in control [
         <a href="#rid7">
          7
         </a>
         ]. Oral medications also are particularly valuable for children with a history of painful defecation, perineal trauma, or difficulty tolerating enemas [
         <a href="#rid13">
          13,32
         </a>
         ]. However, adherence with the necessary volume may be difficult and two to three days (up to a maximum of six days, sometimes split between two weekends) of treatment are often needed to achieve complete disimpaction [
         <a href="#rid33">
          33
         </a>
         ]. In a randomized trial, an oral laxative (
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         ) was found to be as effective as enemas in treating impaction, but children treated with the polyethylene glycol had more fecal incontinence [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with severe impaction, rectal medications may be needed and are typically used in combination with oral medications. Rectal medications are more rapidly effective than oral medications for disimpaction and may be a powerful motivator for toilet sitting [
         <a href="#rid7">
          7,20
         </a>
         ]. However, we avoid their use except in patients with severe impaction because enemas are invasive and may be difficult to administer to an uncooperative or fearful child [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Care setting
         </strong>
         – Disimpaction can usually be performed in the outpatient setting using oral medications, occasionally in combination with rectal medications  (
         <a class="graphic graphic_table graphicRef54749" href="/z/d/graphic/54749.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid27">
          27
         </a>
         ]. It is important to assess the response to the regimen as soon as possible after it is completed. Successful disimpaction is usually indicated by abundant bowel movements with solid stool content and decreased episodes of fecal incontinence [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If one or more attempts at outpatient disimpaction have failed to yield abundant stool, hospitalization may be necessary. In this case, consultation with a pediatric gastroenterologist is also indicated [
         <a href="#rid7">
          7
         </a>
         ]. Inpatient regimens may include nasogastric administration of a balanced electrolyte solution (eg, GoLYTELY) to flush out the colon, sometimes in combination with rectal medication and/or manual disimpaction [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disimpaction regimens
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral medications
         </strong>
         – For most children, we suggest an oral regimen for disimpaction, especially if the impaction is not severe. Polyethylene glycol with or without electrolytes is generally the first-line choice for this purpose due to established efficacy, safety, and tolerability. (See
         <a class="local">
          'Polyethylene glycol'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Outpatients
         </strong>
         – For outpatient disimpaction,
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         (polyethylene glycol without electrolytes; Miralax and others) is generally the most palatable oral laxative and is reasonably well accepted by children [
         <a href="#rid7">
          7
         </a>
         ]. The dose for disimpaction is 1 to 1.5 g/kg/day by mouth for up to six days. The medication is dissolved in approximately 10 mL/kg body weight of water or flavored beverage (some clinicians suggest an electrolyte-containing "sports" beverage for this purpose). In a randomized study, these doses successfully disimpacted 95 percent of children with chronic constipation [
         <a href="#rid35">
          35
         </a>
         ]. An example of this protocol is outlined in the table  (
         <a class="graphic graphic_table graphicRef54749" href="/z/d/graphic/54749.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Patients with inadequate disimpaction using six days of polyethylene glycol-based treatment at home may require escalation of therapy (eg, adding rectal medications or performing polyethylene glycol-electrolyte cleanout in the hospital), as described below.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Other oral agents that have been used successfully for disimpaction include
         <a class="drug drug_pediatric" data-topicid="12614" href="/z/d/drug information/12614.html" rel="external">
          mineral oil
         </a>
         [
         <a href="#rid36">
          36
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="12980" href="/z/d/drug information/12980.html" rel="external">
          magnesium hydroxide
         </a>
         [
         <a href="#rid37">
          37
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="12978" href="/z/d/drug information/12978.html" rel="external">
          magnesium citrate
         </a>
         [
         <a href="#rid38">
          38
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="13405" href="/z/d/drug information/13405.html" rel="external">
          lactulose
         </a>
         [
         <a href="#rid39">
          39
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="12801" href="/z/d/drug information/12801.html" rel="external">
          sorbitol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12786" href="/z/d/drug information/12786.html" rel="external">
          senna
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13080" href="/z/d/drug information/13080.html" rel="external">
          bisacodyl
         </a>
         [
         <a href="#rid37">
          37
         </a>
         ]. We do not generally use these agents for disimpaction, because they are typically less well tolerated than
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         and are probably less effective, based on limited evidence from clinical trials [
         <a href="#rid40">
          40
         </a>
         ]. Furthermore, mineral oil has a risk of lipoid pneumonia if aspirated. (See
         <a class="local">
          'Other laxatives'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Inpatients
         </strong>
         – For inpatient treatment,
         <a class="drug drug_pediatric" data-topicid="12715" href="/z/d/drug information/12715.html" rel="external">
          polyethylene glycol-electrolyte solution
         </a>
         (eg, GoLYTELY) may be given by nasogastric tube at 25 mL/kg/hour up to a maximum of 400 mL/hour until the stool becomes thin, brown liquid [
         <a href="#rid41">
          41
         </a>
         ]. We generally use nasogastric administration because most children are unable to take sufficient quantities of this solution by mouth. The rate of the infusion should be slowed if the child develops vomiting or abdominal distension. Bowel perforation has been reported in children undergoing bowel disimpaction with nasogastric polyethylene glycol-electrolyte solutions, especially in patients with previous bowel surgeries, who may have unrecognized subacute bowel obstruction due to a stricture or an adhesion.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         If there is a large impaction by examination or radiograph, it is prudent to first remove some stool distally by digital disimpaction, rectal softening (
         <a class="drug drug_pediatric" data-topicid="12614" href="/z/d/drug information/12614.html" rel="external">
          mineral oil
         </a>
         retention enema), stimulant rectal suppositories, and/or enemas, before beginning nasogastric solutions, to avoid vomiting.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Pulsed irrigation enhanced-evacuation systems [
         <a href="#rid42">
          42
         </a>
         ] and enemas with Gastrografin have been successfully used for disimpaction when the standard oral and rectal disimpaction regimens described above have been unsuccessful [
         <a href="#rid43">
          43-45
         </a>
         ]. Gastrografin enemas can be administered in or out of the hospital.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Rectal medications
         </strong>
         – For patients with severe impaction, rectal medications may be needed for effective disimpaction [
         <a href="#rid7">
          7,14
         </a>
         ]. Rectal medications are more rapidly effective than oral medications. For patients with severe impactions, they may help reduce the risk for vomiting.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The main options for either outpatient or inpatient treatment are:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Sodium phosphate enema – For children ≥12 years old, use a 4.5-ounce (133 mL) enema (this bottle delivers 118 mL). For children 5 to &lt;12 years old, use a 2.25-ounce (66 mL) enema (this bottle delivers 59 mL). For children 2 to &lt;5 years, use one-half of the 2.25-ounce enema (this delivers approximately 29 mL).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         These enemas should not be used in children younger than two years of age. This dose may be repeated once within 12 to 24 hours, if necessary. Because these are small-volume enemas, the caregiver should be instructed to point the tip of the enema device toward the child's back after it is inserted to direct the contents toward the bowel wall, where it will be effective, rather than into the fecal mass.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         More frequent dosing should be avoided because there are several case reports of life-threatening hyperphosphatemia and hypocalcemic tetany, particularly in young children, those with colonic dysmotility, and/or those with repeated administration of enemas [
         <a href="#rid46">
          46-49
         </a>
         ]. Phosphate-based enemas should be avoided in children with renal insufficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Saline enema – This can be administered using a dose of 10 to 15 mL per kg. When possible, we typically use a prepared
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         solution (eg, an isotonic [0.9%] saline solution intended for intravenous administration), to ensure the appropriate electrolyte concentration.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Mineral oil enema – For children ≥12 years old, use a 4.5-ounce (133 mL) enema (this bottle delivers 118 mL). For children 2 to &lt;12 years, use one-half of the 4.5-ounce bottle (this delivers approximately 59 mL).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_pediatric" data-topicid="13080" href="/z/d/drug information/13080.html" rel="external">
          Bisacodyl
         </a>
         suppositories may be used for older children, and
         <a class="drug drug_pediatric" data-topicid="13337" href="/z/d/drug information/13337.html" rel="external">
          glycerin
         </a>
         suppositories may be used for infants [
         <a href="#rid7">
          7,50
         </a>
         ]. These approaches are generally not as effective as enemas but are well tolerated. (See
         <a class="local">
          'Treatment of constipation in infants'
         </a>
         above and
         <a class="local">
          'Considerations for adolescents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We do
         <strong>
          not
         </strong>
         recommend the use of enemas made of soapsuds [
         <a href="#rid51">
          51,52
         </a>
         ], tap water [
         <a href="#rid53">
          53,54
         </a>
         ], milk and molasses [
         <a href="#rid55">
          55
         </a>
         ], magnesium (ie, Epsom salt) [
         <a href="#rid56">
          56-58
         </a>
         ], or herbal formulations [
         <a href="#rid14">
          14
         </a>
         ], because of potential complications, which include colitis, water intoxication, bowel perforation, and bowel necrosis [
         <a href="#rid7">
          7,14,51,52,59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral and rectal medications
         </strong>
         – Combination treatment with oral and rectal medications is often the most effective approach for moderate or severe fecal impaction. An example of an outpatient protocol that combines
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         (without electrolytes) and
         <a class="drug drug_pediatric" data-topicid="12987" href="/z/d/drug information/12987.html" rel="external">
          sodium phosphate
         </a>
         enemas is outlined in the table  (
         <a class="graphic graphic_table graphicRef54749" href="/z/d/graphic/54749.html" rel="external">
          table 3
         </a>
         ). In this case, the initial treatment is with oral medication to soften the stool and rectal medication is added on day 4 to help evacuate the impacted stool. An alternative combination approach consists of three to four consecutive three-day cycles, in which a phosphate sodium enema is administered on day 1, a
         <a class="drug drug_pediatric" data-topicid="13080" href="/z/d/drug information/13080.html" rel="external">
          bisacodyl
         </a>
         suppository on day 2, and bisacodyl tablet (10 mg) on day 3 [
         <a href="#rid13">
          13,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         After disimpaction, patients should be treated with a maintenance regimen of oral laxatives to "retrain" the bowel and avoid reimpaction. It is important to start this maintenance regimen of laxatives immediately after disimpaction to avoid reaccumulation of stools.
        </p>
        <p class="headingAnchor" id="H3786059146">
         <span class="h3">
          Maintenance laxative therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with no fecal impaction or for those who have successfully completed a disimpaction regimen, the next step in management is a regimen of laxatives, which are given regularly and adjusted to achieve soft daily stools. For most children, the maintenance regimen consists of daily doses of an osmotic laxative, supplemented by intermittent or daily use of stimulant laxatives when needed [
         <a href="#rid6">
          6
         </a>
         ]. An example of a typical maintenance regimen is outlined in the table  (
         <a class="graphic graphic_table graphicRef61175" href="/z/d/graphic/61175.html" rel="external">
          table 4
         </a>
         ). Expert opinion and guidelines encourage aggressive treatment; early intervention appears to lead to more rapid recovery [
         <a href="#rid7">
          7,31
         </a>
         ].
        </p>
        <p>
         The practice of prolonged treatment with osmotic laxatives is supported by extensive clinical experience and a few randomized trials. The laxatives that are considered safe and are used most often for children include
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         (without electrolytes),
         <a class="drug drug_pediatric" data-topicid="12980" href="/z/d/drug information/12980.html" rel="external">
          magnesium hydroxide
         </a>
         (milk of magnesia) and
         <a class="drug drug_pediatric" data-topicid="13405" href="/z/d/drug information/13405.html" rel="external">
          lactulose
         </a>
         . Polyethylene glycol is the best-studied medication and appears to be efficacious and safe, although this is based on low-quality evidence [
         <a href="#rid40">
          40
         </a>
         ]. The type of laxative is not as important as using an adequate dose and ensuring compliance; the choice should be individualized according to circumstances, familiarity, and the child's acceptance [
         <a href="#rid20">
          20,31
         </a>
         ]. The dose should be based upon age, body weight, and severity of constipation  (
         <a class="graphic graphic_table graphicRef63381" href="/z/d/graphic/63381.html" rel="external">
          table 2
         </a>
         ). There is no evidence that tolerance develops to osmotic or lubricant laxatives [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         For patients who do not respond sufficiently or do not tolerate osmotic laxatives, stimulant laxatives (eg,
         <a class="drug drug_pediatric" data-topicid="13080" href="/z/d/drug information/13080.html" rel="external">
          bisacodyl
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12786" href="/z/d/drug information/12786.html" rel="external">
          senna
         </a>
         ) are useful as alternative or adjunctive therapy. Case series and considerable clinical experience suggest that these stimulant laxatives can be used for chronic therapy (eg, one year), tolerance does not develop, and these medications can be eventually weaned off [
         <a href="#rid60">
          60,61
         </a>
         ]. Senna may be helpful in children who have difficulty passing even soft stool because of withholding behavior. However, in the author's personal experience, children treated with senna seem to have more difficulty weaning off of medication as compared with those treated with bisacodyl or other medications. This may be due to the severe clinical phenotype requiring multiple laxatives rather than developing dependence on a stimulant laxative like senna.
        </p>
        <p>
         The parents or caregivers should be advised to adjust the laxative dose according to the response and to increase the dose every two days until the child has one or two soft stools each day or to decrease it if the patient develops diarrhea. They should be warned that the child may continue to have fecal incontinence initially, especially if the child fears or continues to resist having a bowel movement.
        </p>
        <p class="headingAnchor" id="H1822769454">
         <span class="h3">
          Behavior modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         After starting the laxative treatment, the behavioral modification plan should be added. Behavior modification consists of a regular toileting regimen with behavioral reinforcement to encourage cooperation. In children who are not fully toilet trained, we delay this toileting plan until the child has had at least two to four weeks of effective laxative treatment to make sure that the child is not experiencing any pain or hard stools when using the toilet. Because the child's family or caregivers must implement the behavioral protocol, it is important that they be educated about the pathogenesis of constipation, including the cycle of pain, stool withholding, and fecal incontinence, as discussed above  (
         <a class="graphic graphic_figure graphicRef74718" href="/z/d/graphic/74718.html" rel="external">
          figure 1
         </a>
         ). Some institutions offer group educational programs to teach this behavioral modification and report improvement in medication adherence, stool pattern, and fecal incontinence [
         <a href="#rid62">
          62
         </a>
         ]. (See
         <a class="local">
          'Parental education'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         The typical behavior modification program includes [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Toilet sitting – For a child who is toilet trained, the parents or caregivers should implement and supervise a program of regular toilet sitting:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The child should sit on the toilet shortly after a meal for 5 to 10 minutes, two to three times per day [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Toilet sitting episodes should occur at the same time each day and be timed with a timer or stopwatch [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The routine should be followed every day, particularly during times of transition (eg, holidays, vacations, or weekends) [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The child's adherence to the program should be encouraged with positive reinforcers, as described below, rather than negative reinforcers (criticism or punishment).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children whose feet do not touch the floor sitting on a regular toilet seat, it is helpful to use a stool for foot support  (
         <a class="graphic graphic_figure graphicRef119803" href="/z/d/graphic/119803.html" rel="external">
          figure 2
         </a>
         ). A foot support that raises the knees above the level of the hips can help relax the pelvic floor and is particularly helpful for a child who tends to withhold stool. (See
         <a class="medical medical_review" href="/z/d/html/5872.html" rel="external">
          "Recent-onset constipation in infants and children", section on 'Toilet training'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reward system – The parents or caregivers should implement a reward system that is tailored to the child [
         <a href="#rid13">
          13,65
         </a>
         ] and in which the reward is provided for effort (ie, toilet sitting) rather than success (ie, evacuation in the toilet) [
         <a href="#rid21">
          21,66,67
         </a>
         ]. Rewards for preschoolers may include stickers or small sweets, reading books or singing songs while sitting, or special toys that are only used during toilet sitting [
         <a href="#rid13">
          13
         </a>
         ]. Rewards for school-aged children may include reading books together, activity books, or handheld computer games that are only used during sitting time or coins that can be redeemed for small drug store items [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H160438810">
         <span class="h3">
          Management of relapses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapses are common and may be managed in several ways, depending on the severity and history of fecal impaction. One of these steps should be taken if the child has not had a bowel movement for several days:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         has been prescribed, ensure that the parents are mixing it as advised in the correct type and amount of fluid (water, juice, or soda; milk is acceptable if it is not being used for a colonoscopy preparation) and that the child drinks this within 30 minutes and does not sip it throughout the day or bring it to school.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Briefly increase the dose of oral laxative (eg, double the dose for one to three days, until the child is having large soft stools).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give one or two doses of a stimulant laxative, such as
         <a class="drug drug_pediatric" data-topicid="12786" href="/z/d/drug information/12786.html" rel="external">
          senna
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13080" href="/z/d/drug information/13080.html" rel="external">
          bisacodyl
         </a>
         . (See
         <a class="local">
          'Other laxatives'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use an enema to empty the rectum.
        </p>
        <p>
        </p>
        <p>
         If this intervention is successful, treatment is continued with the maintenance osmotic laxative but at a higher dose. If fecal incontinence recurs, a full disimpaction regimen, as described above, may be necessary [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="local">
          'Disimpaction (for select children)'
         </a>
         above.)
        </p>
        <p>
         This approach is sometimes known as "rescue" therapy and is supported by extensive clinical experience and expert guidelines [
         <a href="#rid7">
          7
         </a>
         ]. The development of such a plan empowers the child and family to anticipate, tolerate, and treat recurrences [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H280003682">
         <span class="h3">
          Monitoring and follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         The parents or caregivers should use a diary or log to record bowel movements; use of medications; and episodes of fecal incontinence, abdominal pain, and wetting. A sample of such a diary and a blank one that can be printed out for use by the child's caregivers are shown in the following figures  (
         <a class="graphic graphic_figure graphicRef62849 graphicRef53073" href="/z/d/graphic/62849.html" rel="external">
          figure 3A-B
         </a>
         ).
        </p>
        <p>
         The management of chronic constipation requires monitoring by the clinician or clinician's staff to prevent recurrences. Planned follow-up is particularly important during the first few days of treatment, especially if disimpaction was warranted. The initial discussion can occur by telephone, but the children who continue to pass hard stools may need to return to the office for a more detailed evaluation including a physical examination to evaluate for fecal impaction. Patients who required initial disimpaction also should have an office visit soon after completing the disimpaction protocol to review the progress and transition to maintenance therapy.
        </p>
        <p>
         After entering the maintenance phase, the child should have regular follow-up visits, initially on a monthly basis and then less frequently (eg, every three to four months). The clinician should review the child's stool records  (
         <a class="graphic graphic_figure graphicRef62849 graphicRef53073" href="/z/d/graphic/62849.html" rel="external">
          figure 3A-B
         </a>
         ) and repeat the abdominal and, if needed, rectal examinations [
         <a href="#rid20">
          20,69
         </a>
         ]. The follow-up visits provide opportunities to evaluate progress, adjust medication regimens, anticipate challenges, and celebrate successes [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H235980748">
         <span class="h3">
          Tapering laxative therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the child has achieved regular bowel habits (and independently uses the toilet), the frequency of mandatory toilet sitting and the use of laxatives can be reduced [
         <a href="#rid20">
          20
         </a>
         ]. The laxative dose is gradually decreased to a dose that will prevent fecal incontinence and maintain one to two bowel movements per day [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         We typically wait until optimal bowel habits are achieved and stable for at least six months before laxative use is further decreased or discontinued. In many cases, laxatives need to be taken for months and sometimes years to maintain daily soft stools [
         <a href="#rid15">
          15,70
         </a>
         ]. The parents or caregivers must be warned not to stop the laxative without consulting the child's clinician. Stopping laxatives too soon will likely lead to a prompt recurrence and disrupt the treatment program [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         As laxative therapy is discontinued, it is particularly important to reemphasize compliance with the behavioral and dietary regimens because this may help avoid relapses. In addition, the parents and child should have a "rescue" plan if the child goes more than three days without a stool or has other indications of recurrence (ie, hard stools, abdominal pain, smears in the underwear) [
         <a href="#rid13">
          13
         </a>
         ]. The rescue plan may involve the use of an enema or suppository, followed by an increase in the laxative dose. The development of such a plan empowers the child and family to anticipate, tolerate, and treat recurrences [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="local">
          'Management of relapses'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1666596318">
         <span class="h3">
          Dietary changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         During the treatment of chronic constipation and/or fecal incontinence, it is important to ingest a diet that is conducive to fecal regularity [
         <a href="#rid7">
          7,27
         </a>
         ]. Increased intake of fruit and raw vegetables, bran, and whole-grain breads and cereals is commonly recommended, as is adequate intake of fluids other than milk. However, the evidence supporting these interventions is weak, especially in moderate to severe constipation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fiber
         </strong>
         – We suggest a balanced diet that includes whole grains, fruits, and vegetables as a component of the treatment of constipation in children  (
         <a class="graphic graphic_table graphicRef76461 graphicRef77796" href="/z/d/graphic/76461.html" rel="external">
          table 5A-B
         </a>
         ). Dietary changes should not be forced, nor should they replace the other interventions described above. It is also reasonable to avoid dietary changes in the initial management to allow the family to focus their efforts on medications and toileting behaviors. For children with acute or mild chronic constipation, a reasonable target for dietary fiber can be calculated as the child's age plus 5 to 10 g/day (ie, 11 to 16 g/day for a six-year-old child). Giving more than this fiber goal has no proven benefit for management of constipation in children [
         <a href="#rid7">
          7
         </a>
         ]. For children with a history of fecal impaction, extra fiber intake should be encouraged only after colorectal function has been restored, eg, after several months of successful treatment with laxatives [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adequate intake of fiber may be more important during the time that laxative therapy is discontinued, when the increased stool bulk may raise the child's awareness of the need to evacuate [
         <a href="#rid14">
          14
         </a>
         ]. Supplementation with glucomannan was a useful adjunct to disimpaction and behavioral interventions in a small randomized trial [
         <a href="#rid71">
          71
         </a>
         ]. If necessary, a variety of fiber products are available over the counter (
         <a class="drug drug_pediatric" data-topicid="12749" href="/z/d/drug information/12749.html" rel="external">
          psyllium
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="135059" href="/z/d/drug information/135059.html" rel="external">
          wheat dextrin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="135074" href="/z/d/drug information/135074.html" rel="external">
          methylcellulose
         </a>
         ). Preparations include powdered fiber (which can be mixed into juice or frozen into popsicles), wafers, or tablets [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although increasing the intake of fiber is often recommended for acute and chronic constipation, the evidence base for this practice is weak and somewhat conflicting [
         <a href="#rid7">
          7,71-76
         </a>
         ]. This may be because dietary fiber can have either beneficial or adverse effects in children with constipation, especially in the setting of chronic constipation and recurrent impactions. On the one hand, fiber adds bulk and water content to the stool; this can make the stool softer and easier to release. On the other hand, the increased stool bulk also may cause greater distension of the rectum and colon in children with fecal retention and interfere with the child's ability to sense the need to defecate. Moreover, if there is inadequate accompanying fluid intake, impactions can occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluid intake
         </strong>
         – To ensure adequate hydration, children with chronic constipation or fecal incontinence should be encouraged to consume at least 32 to 64 ounces (960 to 1920 mL) of water or other nonmilk liquids per day, particularly if they are using fiber supplements. Contrary to popular belief, there is no evidence that constipation can be successfully treated by increasing fluid intake unless the patient is clinically dehydrated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether increasing fluids beyond the usual intake affects constipation is unclear. In one study, 108 prepubertal children (2 to 12 years of age) with moderate to severe simple constipation were randomly assigned to one of three groups: One was instructed to increase daily water intake by 50 percent, the second to ingest additional hyperosmolar liquids such as juices, and the third to make no changes [
         <a href="#rid77">
          77
         </a>
         ]. There were no changes regarding stool frequency or consistency or ease of defecation with either intervention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cow's milk
         </strong>
         – In children whose constipation is unresponsive to other noninvasive measures (behavioral and dietary interventions, with or without oral laxatives) and especially in those with atopic symptoms, we suggest a trial for at least two weeks of eliminating all cow's milk protein from the diet [
         <a href="#rid7">
          7,19,78
         </a>
         ]. If the constipation improves substantially, the diet should be continued. A nondairy form of milk (eg, soy) can be used as a substitute.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Eliminating cow's milk from the diet improves constipation in some children. This is particularly true in children with atopic symptoms, probably because of an occult cow's milk intolerance [
         <a href="#rid78">
          78,79
         </a>
         ]. In one double-blind crossover study in 65 constipated children who were refractory to laxative therapy, 68 percent of children improved while receiving soy milk compared with cow's milk [
         <a href="#rid80">
          80,81
         </a>
         ]. Constipation recurred within days of reintroduction of cow's milk. Another study suggested that constipation can be a delayed clinical manifestation of cows' milk protein intolerance, particularly in children with a personal or family history of atopy [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although not clinically proven, it is also possible that excessive consumption of milk may contribute to constipation in some children, even in the absence of cow's milk protein intolerance. The proposed mechanism is that cow's milk slows intestinal motility and satiates the child, thereby diminishing the intake of other fluids and fiber-containing foods. This mechanism may be most relevant for toddlers, who are most likely to have a high intake of milk and low intake of dietary fiber. Therefore, we recommend limiting the intake of cow's milk to 24 fluid ounces (720 mL) per day.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H427631410">
         <span class="h2">
          Considerations for adolescents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compared with younger children, adolescents with chronic constipation are more likely to have longstanding symptoms and are less likely to respond to the combination of behavioral intervention, dietary changes, and osmotic laxatives described above. Adolescents are also more likely to have abnormal colonic motility, such as slow-transit constipation. (See
         <a class="medical medical_review" href="/z/d/html/99538.html" rel="external">
          "Functional constipation in infants, children, and adolescents: Clinical features and diagnosis", section on 'Slow-transit constipation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99538.html" rel="external">
          "Functional constipation in infants, children, and adolescents: Clinical features and diagnosis", section on 'Contributing factors'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the abdominal pain persists despite successful treatment of constipation with a laxative, constipation-predominant irritable bowel syndrome should be considered. (See
         <a class="medical medical_review" href="/z/d/html/112.html" rel="external">
          "Functional abdominal pain in children and adolescents: Management in primary care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2630.html" rel="external">
          "Clinical manifestations and diagnosis of irritable bowel syndrome in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For adolescents with a short history of chronic constipation or mild symptoms and no evidence of an organic cause (see
         <a class="medical medical_review" href="/z/d/html/99538.html" rel="external">
          "Functional constipation in infants, children, and adolescents: Clinical features and diagnosis"
         </a>
         ), the first step is to treat with osmotic laxatives  (
         <a class="graphic graphic_table graphicRef63381" href="/z/d/graphic/63381.html" rel="external">
          table 2
         </a>
         ) and dietary changes, as outlined above, with disimpaction if needed. (See
         <a class="local">
          'Stepwise approach to bowel retraining'
         </a>
         above and
         <a class="local">
          'Disimpaction (for select children)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For some adolescents and especially those with a long history of constipation, high doses and prolonged courses of laxatives may be needed, with behavioral support to promote adherence to the regimen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all adolescents, screen for behavioral and psychosocial comorbidities that may promote or exacerbate the constipation, including attention deficit hyperactivity disorder (ADHD) [
         <a href="#rid83">
          83
         </a>
         ], school stressors, and eating disorders, and refer for further evaluation and treatment as indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the above strategies are not successful, additional pharmacologic options for adolescents include
         <a class="drug drug_pediatric" data-topicid="141759" href="/z/d/drug information/141759.html" rel="external">
          linaclotide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">
          lubiprostone
         </a>
         , or
         <a class="drug drug_general" data-topicid="83328" href="/z/d/drug information/83328.html" rel="external">
          prucalopride
         </a>
         . (See
         <a class="local">
          'Other laxatives'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In refractory cases, further evaluation of colonic motility and anorectal function may be useful to define the underlying cause and guide treatment (see
         <a class="medical medical_review" href="/z/d/html/5906.html" rel="external">
          "Constipation in infants and children: Evaluation", section on 'Motility testing for patients with functional constipation refractory to treatment'
         </a>
         ). For those with dyssynergic defecation, biofeedback therapy may be useful. (See
         <a class="local">
          'Treatment failure'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fecal incontinence associated with chronic constipation is especially distressing for adolescent patients. In addition to achieving regular, painless bowel movements, treatment goals should also include achieving social continence [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2751059886">
         <span class="h1">
          TREATMENT FAILURE
         </span>
        </p>
        <p class="headingAnchor" id="H2497599388">
         <span class="h2">
          Reinforcement and intensification of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Failure of treatment, manifested by recurrent impaction and/or continued fecal incontinence, suggests the need to review education and other treatment components. Most treatment failures are caused by inadequate medication or premature discontinuation [
         <a href="#rid14">
          14
         </a>
         ]. Poor adherence with the treatment program is another important cause of treatment failure. In some children, adherence to the medication or behavioral program may be impaired by behavioral problems (eg, oppositional behavior, poor attention span, high activity level) [
         <a href="#rid20">
          20,27,85
         </a>
         ]. Such patients and their families may benefit from individual or group psychotherapy and a more rigorous behavioral approach [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H576244313">
         <span class="h2">
          Further evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Repeated failure despite adequate compliance with a maximal laxative regimen (eg, daily use of an osmotic and stimulant laxative) requires reconsideration of the diagnosis and the possibility of further testing [
         <a href="#rid7">
          7
         </a>
         ]. Patients with ongoing chronic constipation despite adherence to an optimal medical and behavioral intervention should be evaluated by anorectal manometry and/or balloon expulsion testing. These tests can also help identify patients with internal anal sphincter (IAS) achalasia or other anatomic causes of constipation, as well as dyssynergic defecation, which is a functional disorder characterized by the incomplete evacuation of fecal material from the rectum due to paradoxical contraction or failure to relax pelvic floor muscles when straining to defecate (see
         <a class="medical medical_review" href="/z/d/html/5906.html" rel="external">
          "Constipation in infants and children: Evaluation", section on 'Motility testing for patients with functional constipation refractory to treatment'
         </a>
         ). Colon transit studies using Sitz markers or radioisotopes can help evaluate oro-anal transit and colon manometry studies can identify regional or pancolonic dysmotility. Slow transit or regional and pancolonic dysmotility have been associated with chronic refractory symptoms.
        </p>
        <p class="headingAnchor" id="H1594201011">
         <span class="h2">
          Specific interventions for selected patients
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biofeedback therapy
         </strong>
         – For the subset of patients with dyssynergic defecation, biofeedback therapy is occasionally added as an adjunct to medical and behavioral therapy. However, it requires a highly motivated patient and its efficacy in the pediatric age group is uncertain. Because biofeedback requires serial learning sessions with an anal probe and exercises, it is only practical for use in highly motivated older children and adolescents. (See
         <a class="medical medical_review" href="/z/d/html/99538.html" rel="external">
          "Functional constipation in infants, children, and adolescents: Clinical features and diagnosis", section on 'Dyssynergic defecation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children with constipation but without dyssynergic defecation, there is no evidence that biofeedback has benefits over laxatives alone [
         <a href="#rid87">
          87-89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anal sphincter release (botulinum toxin injection or anal sphincter myectomy)
         </strong>
         – Some children with constipation refractory to medical therapy may respond to an intervention to release the IAS through injection of botulinum toxin or myectomy. The effect of the botulinum toxin treatment is temporary (lasting up to several months). Complications occur in fewer than 1 percent of patients and may include transient urinary incontinence, increased fecal incontinence, or pelvic muscle paresis [
         <a href="#rid90">
          90
         </a>
         ]. For patients who respond to initial treatments, additional injections may be given every few months, as needed, to maintain efficacy over the long term. Alternatively, they can proceed to surgical myectomy, which may provide more durable benefits. Limited information is available to guide selection of patients for surgical approaches [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These interventions have been used successfully in:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with IAS achalasia
         </strong>
         – Botulinum toxin injection and anal sphincter myectomy are established interventions for patients with IAS achalasia, which is characterized by absence of the rectoanal inhibitory reflex on anorectal manometry (with exclusion of Hirschsprung disease by rectal suction biopsy). Both interventions are effective in 60 to 80 percent of patients. In a meta-analysis of studies comparing these treatments for IAS achalasia, patients undergoing myectomy reported more frequent bowel movements, but there were no significant differences in long-term laxative use between the two treatment modalities [
         <a href="#rid92">
          92,93
         </a>
         ]. Interestingly, short-term fecal incontinence was more common with botulinum toxin injection compared with myectomy. Thus, myectomy appears to be more effective than botulinum toxin for some patients. Anal sphincter myectomy is a technically difficult operation, and a majority of data on the role of myectomy for IAS achalasia has come from a single center with a very experienced pediatric surgeon. (See
         <a class="medical medical_review" href="/z/d/html/99538.html" rel="external">
          "Functional constipation in infants, children, and adolescents: Clinical features and diagnosis", section on 'Internal anal sphincter achalasia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with functional constipation
         </strong>
         – Botulinum toxin injection also may be useful for children with refractory idiopathic chronic constipation (ie, with no apparent IAS dysfunction) who do not respond to other interventions such as laxatives or pelvic physical therapy/biofeedback. Retrospective studies and one randomized trial report improvement in painful defecation and soiling in a majority of such patients after botulinum toxin injection [
         <a href="#rid90">
          90,94-96
         </a>
         ]. By contrast, another randomized trial reported no significant improvement in children who received botulinum toxin in addition to standard care, but this finding may have been skewed by the relatively weak laxatives (only
         <a class="drug drug_pediatric" data-topicid="12786" href="/z/d/drug information/12786.html" rel="external">
          senna
         </a>
         ) used in the standard care protocol [
         <a href="#rid97">
          97
         </a>
         ]. Additional studies are underway to identify whether specific groups of children may benefit from this therapy (eg, those with developmental delay, sensory integration issues, or a high degree of anxiety surrounding defecation).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other surgical interventions
         </strong>
         – The rare patient with intractable constipation and normal anorectal manometry (or one who fails to respond to botulinum toxin injection) may be considered for sacral nerve stimulation or for other surgical approaches:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sacral nerve stimulation appears to be a promising new treatment option for children with chronic constipation, especially those who are unresponsive to intensive medical management [
         <a href="#rid98">
          98-100
         </a>
         ]. In a series of 70 children with persistent fecal incontinence despite a bowel management (two-thirds were idiopathic) who were treated with sacral nerve stimulation, the proportion with at least weekly episodes of incontinence decreased from 49 to 19 percent (daytime) and from 35 to 7 percent (nighttime) [
         <a href="#rid99">
          99
         </a>
         ]. Forty percent required a reoperation, usually for lead or battery malfunction; the median time to reoperation was 5.2 years. Since it also helps to improve urinary incontinence, this treatment may be especially suited to patients with combined fecal and urinary incontinence [
         <a href="#rid100">
          100
         </a>
         ]. One study reported benefits of a percutaneous tibial nerve stimulation approach [
         <a href="#rid101">
          101
         </a>
         ]. Larger randomized studies with long-term follow-up are required. The experience with sacral nerve stimulation in adults is described separately. (See
         <a class="medical medical_review" href="/z/d/html/96913.html" rel="external">
          "Fecal incontinence in adults: Management", section on 'Sacral nerve stimulation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other surgical procedures include antegrade continence enema (ACE) [
         <a href="#rid102">
          102-107
         </a>
         ], intestinal diversion (ileostomy or colostomy) [
         <a href="#rid102">
          102,108
         </a>
         ], or colonic resection [
         <a href="#rid102">
          102,109,110
         </a>
         ], as summarized in a systematic review [
         <a href="#rid91">
          91
         </a>
         ]. ACE provides a conduit for daily colonic irrigation and is also used for patients with myelomeningocele and bowel dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/6219.html" rel="external">
          "Myelomeningocele (spina bifida): Management and outcome", section on 'Bowel management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A retrospective series of 44 patients reported the following outcomes of surgical interventions [
         <a href="#rid102">
          102
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ACE was performed in 16 patients and had a satisfactory outcome in 10 (63 percent). These patients generally required ongoing ACE treatment throughout the follow-up period but displayed some improvement in colonic motility after one year of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Diversion procedures (with ileostomy or colostomy) were performed in 19 patients and had satisfactory outcomes in 18 (95 percent); intestinal continuity was reestablished in 14 (74 percent) at a mean of 27 months post-diversion. Those with colonic dysmotility as documented by manometry underwent resection of the dysfunctional segment at the time of reanastomosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Colonic resection was performed in nine patients and yielded satisfactory outcome in only two (22 percent), either because of persistent constipation or fecal incontinence. Four of the nine patients (44 percent) required a second surgical procedure. Somewhat better outcomes were reported in a separate systematic review [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Based on this and other anecdotal reports, we feel that colonic resection should not be offered as a treatment for refractory constipation. Rarely, ACE procedures and diversion via colostomy or ileostomy with subsequent resection and reanastomosis may be appropriate. A systematic review provides a summary of studies using these techniques, concluding that there is insufficient evidence to support one technique over the others [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4224689554">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Improvement can be expected in virtually all patients who adhere to the type of comprehensive approach described above [
         <a href="#rid17">
          17,19,64,111,112
         </a>
         ]. On the other hand, complete recovery (defined as three or more bowel movements weekly with no fecal incontinence while off of laxatives) is seen less often [
         <a href="#rid19">
          19,20,22,113
         </a>
         ]. A systematic review was unable to identify factors that predict which patients would fail to respond to treatment [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
         Recovery rates increase significantly over time: approximately 30 to 50 percent after one year and 48 to 75 percent after five years [
         <a href="#rid19">
          19,22,112,115
         </a>
         ]. Recovery rates are higher in populations in primary care practices, presumably because this population includes children with less severe or refractory constipation as compared with children referred for specialty care [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Most children with functional constipation who are adequately treated during childhood will have good clinical outcomes in adulthood. In a study of 401 children treated with a six- to eight-week treatment protocol in the Netherlands and followed for a median of 11 years, 75 percent had no symptoms as adults [
         <a href="#rid116">
          116
         </a>
         ]. Risk factors for lack of long-term recovery included older age at onset, longer delay before referral to a pediatric gastroenterologist, and fewer bowel movements per week at presentation.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DETAILS ON MEDICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H10191134">
         <span class="h2">
          Polyethylene glycol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          Polyethylene glycol 3350
         </a>
         (polyethylene glycol without electrolytes, eg, Miralax, Glycolax, or Restoralax) is an osmotic laxative. Because it is more palatable and has fewer adverse effects than other agents, polyethylene glycol 3350 is preferred by most experts for disimpaction and treatment of chronic constipation, although it is not labeled for this use [
         <a href="#rid7">
          7
         </a>
         ]. It is approved for short-term management of constipation in adults and is available without prescription in the United States.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The typical dose of
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         is 0.4 to 0.8 g/kg/day (up to 17 g)  (
         <a class="graphic graphic_table graphicRef63381" href="/z/d/graphic/63381.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid117">
          117-120
         </a>
         ]. One capful (17 g) should be mixed with 8 oz of water, juice, or soda (and not milk) and taken within 30 minutes. The osmotic effect is substantially diminished if the dose is spread out over a longer time (eg, taken in sips throughout the day). For optimal adherence, we generally advise the parents or caregiver not to have the child take the dose at school.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a dose-ranging trial, the dose of 0.4 g/kg/day was most likely to give high success rates (74 percent), while generating fewer complaints of abdominal pain or fecal incontinence than higher doses [
         <a href="#rid121">
          121
         </a>
         ]. The effective dose in an individual patient is not predictable, and many patients require relatively high initial treatment doses with somewhat lower maintenance doses. Therefore, we suggest an empiric approach to dosing. In our practice, we use an initial dose of 4 tsp (17 g = approximately 4.5 tsp) for patients weighing 20 kg or more, increasing or decreasing by 0.5 tsp to 1 tsp every other day until the consistency of the stools is soft to loose. We have rarely had to use more than 6 to 7 tsp per day. For patients weighing less than 20 kg, it is reasonable to use a slightly lower initial dose (0.4 to 0.8 g/kg/day), with dose adjustments up or down to achieve soft stools. Further dose-ranging trials are needed to determine optimal dosing, especially in children requiring long-term polyethylene glycol treatment [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Adverse effects of polyethylene glycol include diarrhea (10 percent), bloating or flatulence (6 percent), and abdominal pain (2 percent) [
         <a href="#rid119">
          119
         </a>
         ]. These symptoms tend to be mild, transient, and responsive to dose reduction [
         <a href="#rid33">
          33
         </a>
         ]. Short- and long-term studies revealed no significant changes in serum electrolytes or other laboratory tests during treatment with polyethylene glycol [
         <a href="#rid9">
          9,122
         </a>
         ]. Theoretical concerns have been raised as to whether polyethylene glycol might cause neuropsychiatric effects, eg, due to neurotoxic effects of ethylene glycol, a polyethylene glycol metabolite. To investigate this possibility, one study measured serum concentrations of polyethylene glycol metabolites after an oral dose of PEG and found that serum concentrations of ethylene glycol and one other polyethylene glycol metabolite increase transiently, peaking 90 minutes after the dose of polyethylene glycol but remaining well below the threshold for toxicity, then returning to levels that are found in controls [
         <a href="#rid123">
          123
         </a>
         ]. The total dose of ethylene glycol ingested with chronic use of polyethylene glycol is estimated to be less than 1/15
         <sup>
          th
         </sup>
         of the amount allowed by the Environmental Protection Agency in drinking water. Thus, neurotoxicity is very unlikely with acute or chronic use of polyethylene glycol. Behavioral symptoms that are occasionally reported in children during polyethylene glycol treatment are more likely related to the known association of constipation with comorbid neuropsychiatric conditions [
         <a href="#rid124">
          124
         </a>
         ]. The North American Society For Pediatric Gastroenterology, Hepatology and Nutrition has published a
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fnaspghn.informz.net%2FNASPGHN%2Fdata%2Fimages%2FPEG+3350+FAQ.pdf&amp;token=F0XDY3ibS5ERTd%2BbTwz%2FsMpB19z5HAgc1mBrjcRd9ZoGA0SBl4%2FKLUoX8ePoatjCWC6D%2F0r4XXLqYrtNESMoX6yLYjN0ryVSyxO5d%2BThaH8%3D&amp;TOPIC_ID=5873" target="_blank">
          statement
         </a>
         with frequently asked questions about the use of polyethylene glycol in children [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Clinical trials indicate that
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         (without electrolytes) has similar or greater efficacy than that of
         <a class="drug drug_pediatric" data-topicid="13405" href="/z/d/drug information/13405.html" rel="external">
          lactulose
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12980" href="/z/d/drug information/12980.html" rel="external">
          magnesium hydroxide
         </a>
         , with fewer adverse effects and greater acceptance [
         <a href="#rid122">
          122,126-129
         </a>
         ]. In particular, a systematic review concluded that polyethylene glycol is superior to either lactulose or milk of magnesia for outcomes of higher frequency of bowel movements and reduced need for additional therapy, although the difference was small and the quality of the evidence was weak [
         <a href="#rid40">
          40
         </a>
         ]. Patients tolerated polyethylene glycol as well or better than the other therapies, suggesting the possibility that polyethylene glycol is associated with improved treatment adherence (eg, 95 versus 65 percent in one study) [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternate formulations
         </strong>
         – Oral preparations of polyethylene glycol
         <strong>
          with
         </strong>
         electrolytes (Transipeg, Movicol, Movicolon) are available outside of the United States. The addition of electrolytes offers the theoretical benefit of avoiding electrolyte depletion, but this also alters the taste, which may decrease palatability. One trial from the Netherlands compared the efficacy of polyethylene glycol with electrolytes (Transipeg) to
         <a class="drug drug_pediatric" data-topicid="13405" href="/z/d/drug information/13405.html" rel="external">
          lactulose
         </a>
         in 100 children with functional constipation [
         <a href="#rid130">
          130
         </a>
         ]. Compared with the pretreatment period, defecation frequency increased, and episodes of fecal incontinence decreased in both groups after eight weeks of therapy. However, success (defined as ≥3 bowel movements per week and ≤1 episode of fecal incontinence every two weeks) occurred more frequently in the polyethylene glycol group (56 versus 29 percent). Children in the polyethylene glycol group reported less abdominal pain, straining, and pain at defecation but complained of bad taste more often than did those in the lactulose group. Similar results were reported in a smaller study [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3500521651">
         <span class="h2">
          Other laxatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several other types of laxatives may be appropriate and useful:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mineral oil
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12614" href="/z/d/drug information/12614.html" rel="external">
          Mineral oil
         </a>
         is a lubricant laxative that was often used in the past for chronic constipation and fecal incontinence. It has largely been replaced by osmotic laxatives, which appear safer and at least as effective as mineral oil, as well as more palatable and easier to administer.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cautions and adverse effects –
         <a class="drug drug_pediatric" data-topicid="12614" href="/z/d/drug information/12614.html" rel="external">
          Mineral oil
         </a>
         can cause a dangerous lipoid pneumonia if aspirated [
         <a href="#rid131">
          131,132
         </a>
         ]. Therefore, it should not be used in patients at risk for aspiration, including infants (&lt;12 months of age), children with neurodevelopmental abnormalities, or those with gastroesophageal reflux. For the same reason, it should not be used if it causes nausea or vomiting, even in otherwise healthy children. There is a theoretic concern that chronic use of mineral oil may interfere with the absorption of fat-soluble vitamins, but any effects are probably clinically insignificant. In addition, this effect can be minimized by administering it in the mid-afternoon and at bedtime and/or by prescribing a daily multivitamin [
         <a href="#rid13">
          13,68,133,134
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Administration – Typical doses of
         <a class="drug drug_pediatric" data-topicid="12614" href="/z/d/drug information/12614.html" rel="external">
          mineral oil
         </a>
         are 1 to 2 mL/kg/day, once or in divided doses (maximum 45 mL/day), with dose adjustment to achieve soft stools  (
         <a class="graphic graphic_table graphicRef63381" href="/z/d/graphic/63381.html" rel="external">
          table 2
         </a>
         ). Mineral oil, particularly in large amounts, may not be palatable in children. It may be more palatable if served chilled and mixed in a 1:1 ratio with a fat-containing food that the child likes (eg, pudding, yogurt, chocolate syrup) [
         <a href="#rid13">
          13
         </a>
         ]. Families should be warned about the possibility of anal leakage of mineral oil, which may stain clothing or furniture. If anal leakage of oil occurs, this usually indicates either a need for disimpaction or that the dose of mineral oil is excessive.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Efficacy – In one randomized trial in 37 children (3 to 13 years old) with chronic functional constipation,
         <a class="drug drug_pediatric" data-topicid="12614" href="/z/d/drug information/12614.html" rel="external">
          mineral oil
         </a>
         compared favorably to
         <a class="drug drug_pediatric" data-topicid="12786" href="/z/d/drug information/12786.html" rel="external">
          senna
         </a>
         concentrate (a stimulant laxative) in symptom control, frequency of recurrence, and duration of therapy [
         <a href="#rid135">
          135
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Magnesium hydroxide
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12980" href="/z/d/drug information/12980.html" rel="external">
          Magnesium hydroxide
         </a>
         (milk of magnesia) is an osmotic laxative that has a long history of success but has been largely replaced by
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         because of palatability and, possibly, lower efficacy [
         <a href="#rid40">
          40
         </a>
         ]. It releases cholecystokinin, which stimulates gastrointestinal motility and secretion. Magnesium hydroxide should be avoided in infants or patients with renal insufficiency since they are susceptible to hypermagnesemia [
         <a href="#rid136">
          136-139
         </a>
         ]. Typical doses are 1 to 2 mL/kg once daily (of 400 mg/5 mL solution)  (
         <a class="graphic graphic_table graphicRef63381" href="/z/d/graphic/63381.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lactulose
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13405" href="/z/d/drug information/13405.html" rel="external">
          Lactulose
         </a>
         is an osmotic laxative and is usually well tolerated in the long-term [
         <a href="#rid7">
          7
         </a>
         ]. Lactulose is not absorbed by the small intestine. Some patients report loss of effectiveness over time, presumably due to enhanced degradation by the colonic bacteria. Side effects include flatulence and abdominal cramps, which occur when the sugar is metabolized by colonic flora. Typical doses are 1 mL/kg (up to 30 mL) once or twice daily  (
         <a class="graphic graphic_table graphicRef63381" href="/z/d/graphic/63381.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stimulant laxatives
         </strong>
         – Stimulant laxatives, such as
         <a class="drug drug_pediatric" data-topicid="12786" href="/z/d/drug information/12786.html" rel="external">
          senna
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13080" href="/z/d/drug information/13080.html" rel="external">
          bisacodyl
         </a>
         , are sometimes used for brief periods to avoid recurrence of impaction ("rescue" therapy), and their use for this purpose is supported by extensive clinical experience and expert guidelines [
         <a href="#rid7">
          7
         </a>
         ], although controlled trials on the use of these agents for constipation in children are lacking [
         <a href="#rid140">
          140
         </a>
         ]. Traditionally, concerns were raised about the possible development of tolerance or physical dependence with chronic use of stimulant laxatives. The issue has not been systematically studied in humans, but it appears that most patients remain responsive to these drugs with chronic use [
         <a href="#rid60">
          60
         </a>
         ]. Nonetheless, most pediatric providers reserve stimulant laxatives for patients with severe constipation who do not respond to osmotic laxatives and dietary changes, preferably under supervision from a pediatric gastroenterologist [
         <a href="#rid141">
          141
         </a>
         ]. These laxatives are often used in conjunction with stool softeners such as
         <a class="drug drug_pediatric" data-topicid="13244" href="/z/d/drug information/13244.html" rel="external">
          docusate
         </a>
         (Colace) or in addition to osmotic agents such as
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         . Stimulant laxatives also may be helpful for patients with anorectal malformations or other disorders that affect anorectal innervation, which can affect sensory and motor function and predispose to both constipation and fecal incontinence [
         <a href="#rid142">
          142
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Newer pharmacologic agents
         </strong>
         – The following drugs are second-line agents for chronic constipation in adults (bulk-forming and osmotic laxatives are preferred) (see
         <a class="medical medical_review" href="/z/d/html/2636.html" rel="external">
          "Management of chronic constipation in adults", section on 'Pharmacologic therapy'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="141759" href="/z/d/drug information/141759.html" rel="external">
          Linaclotide
         </a>
         (Linzess) – A guanylate cyclase receptor agonist (approved in the United States for children ≥6 years) [
         <a href="#rid143">
          143,144
         </a>
         ]. Adverse effects include diarrhea, which can be severe.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10195" href="/z/d/drug information/10195.html" rel="external">
          Lubiprostone
         </a>
         (Amitiza) – A chloride channel activator (not approved in children). In a randomized trial in 606 pediatric patients with chronic functional constipation, lubiprostone was not more effective than placebo, although it was generally well tolerated [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="83328" href="/z/d/drug information/83328.html" rel="external">
          Prucalopride
         </a>
         (Motegrity, Resotran, Resolor) – A serotonin receptor agonist that enhances bowel motility (not approved in children). Although clinical trials have suggested that prucalopride is efficacious in adults, a large, randomized study in children found no efficacy compared with placebo [
         <a href="#rid146">
          146
         </a>
         ]. These findings do not exclude the possibility that prucalopride may be effective for subsets of children, such as those who are older (≥12 years of age) or those who have slow-transit constipation [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3942250">
         <span class="h2">
          Probiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely recommend probiotics for treatment of constipation in children, because the available evidence from controlled trials in children and adults is insufficient to determine efficacy or to identify the most effective strain, dose, or treatment duration [
         <a href="#rid7">
          7,148-150
         </a>
         ]. On the other hand, standard probiotic preparations are probably safe, provided that the child is not immunosuppressed.
        </p>
        <p>
         The hypothesis that probiotics may have therapeutic potential for the treatment of constipation is supported by data demonstrating differences in the intestinal microbiota between healthy individuals and patients with chronic constipation [
         <a href="#rid151">
          151
         </a>
         ]. Administration of
         <em>
          Bifidobacterium
         </em>
         or
         <a class="drug drug_pediatric" data-topicid="13404" href="/z/d/drug information/13404.html" rel="external">
          Lactobacillus
         </a>
         has also been shown to improve colonic transit times in constipated patients [
         <a href="#rid152">
          152,153
         </a>
         ]. Only a few clinical trials in children have addressed the use of probiotics for constipation, with mixed results [
         <a href="#rid154">
          154-157
         </a>
         ]. The experience with probiotics for constipation in adults is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2603.html" rel="external">
          "Probiotics for gastrointestinal diseases", section on 'Constipation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3237799979">
         <span class="h1">
          INDICATIONS FOR REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consultation with a pediatric gastroenterologist should be considered in children in whom oral or rectal medications are ineffective for disimpaction and in whom dietary changes and laxative therapy are ineffective for maintenance therapy [
         <a href="#rid7">
          7
         </a>
         ]. Additional evaluation before or after consultation should include thyroxine (T4), thyroid-stimulating hormone (TSH), calcium, celiac disease antibodies, and lead. For children with atypical features or constipation that is refractory to optimal medical and behavioral therapy, diagnostic testing may include tests of colonic transit and anorectal and colonic manometry. (See
         <a class="local">
          'Further evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5906.html" rel="external">
          "Constipation in infants and children: Evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H213257122">
         <span class="h1">
          TREATMENT OF NONRETENTIVE FECAL INCONTINENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonretentive fecal incontinence is the term used to describe fecal incontinence that occurs in the
         <strong>
          absence
         </strong>
         of constipation or other organic disease. Children with this disorder usually have full bowel movements in their clothing rather than just minor episodes of fecal incontinence. Treatment typically involves behavior modification and sometimes dietary changes, without laxative therapy [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         It is important to distinguish this disorder from constipation-associated fecal incontinence, which is far more common (in children with fecal incontinence, 80 percent have associated constipation). Children with fecal incontinence should have a careful evaluation for underlying constipation, including a digital rectal examination and, in some cases, a colonic transit study using radiopaque markers, because constipation is not always recognized by the child or caregiver. (See
         <a class="medical medical_review" href="/z/d/html/5859.html" rel="external">
          "Functional fecal incontinence in infants and children: Definition, clinical manifestations, and evaluation", section on 'Further evaluation'
         </a>
         .)
        </p>
        <p>
         No widely effective treatments have been established for nonretentive fecal incontinence, but most approaches focus on behavior modification and psychosocial evaluation and support [
         <a href="#rid23">
          23
         </a>
         ]. The behavioral protocol generally includes a highly structured toilet training protocol designed to encourage frequent and sustained efforts at defecation and supported by behavior modification techniques, including a reward system. Laxatives, enemas, and biofeedback are not helpful in these children (provided that occult constipation has been carefully excluded) [
         <a href="#rid89">
          89,158,159
         </a>
         ]. In our practice, we find that many of these children benefit from referral to a therapist for behavioral intervention and support.
        </p>
        <p>
         Only one study has reported long-term outcomes in patients with nonretentive fecal incontinence, and this suggested very slow resolution of the problem [
         <a href="#rid160">
          160
         </a>
         ]. Among children who had intensive medical and behavioral treatment for two years, only 29 percent had resolved after two years of treatment, 65 percent after five years, and approximately 90 percent after 10 years.
        </p>
        <p class="headingAnchor" id="H431249898">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115341.html" rel="external">
          "Society guideline links: Constipation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15387.html" rel="external">
          "Patient education: Constipation in children (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/86715.html" rel="external">
          "Patient education: Fecal incontinence in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/1215.html" rel="external">
          "Patient education: Constipation in infants and children (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants
         </strong>
         – Treatment of infants may include osmotically active carbohydrates such as sorbitol-containing juices (eg, apple, prune, or pear), with osmotic laxatives and/or occasional
         <a class="drug drug_pediatric" data-topicid="13337" href="/z/d/drug information/13337.html" rel="external">
          glycerin
         </a>
         suppositories, if necessary. Glycerin suppositories should be used with caution because they can cause anal irritation.
         <a class="drug drug_pediatric" data-topicid="12614" href="/z/d/drug information/12614.html" rel="external">
          Mineral oil
         </a>
         , enemas, and stimulant laxatives should
         <strong>
          not
         </strong>
         be used in infants, due to safety concerns. (See
         <a class="local">
          'Treatment of constipation in infants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Functional constipation with or without fecal incontinence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          General strategy
         </strong>
         – Treatment of constipation in children typically includes four general steps for bowel retraining. It is essential to educate and engage parents or caregivers in each of these steps, including the need for prolonged therapy to "retrain" the bowel  (
         <a class="graphic graphic_figure graphicRef74718" href="/z/d/graphic/74718.html" rel="external">
          figure 1
         </a>
         ). Improvement can be expected in the majority of such patients, although it may be gradual (see
         <a class="local">
          'General approach and goals'
         </a>
         above and
         <a class="local">
          'Parental education'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Disimpaction (for children with a large stool mass or fecal incontinence)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Prolonged laxative treatment and behavior therapy to achieve regular evacuation and avoid recurrent constipation
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Dietary changes (primarily increasing fiber content) to maintain soft stools
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Gradual tapering and withdrawal of laxatives as tolerated
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Disimpaction
         </strong>
         – Disimpaction can be accomplished with oral medications, rectal medications, or a combination  (
         <a class="graphic graphic_table graphicRef54749" href="/z/d/graphic/54749.html" rel="external">
          table 3
         </a>
         ). We suggest using oral rather than rectal medications for most children and particularly in those with a history of painful defecation or perineal trauma (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Enemas or brief hospitalization for disimpaction may be necessary for children with severe constipation or when rapid disimpaction is desired. (See
         <a class="local">
          'Disimpaction (for select children)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bowel retraining
         </strong>
         – After disimpaction, we suggest treating children with chronic constipation (with or without fecal incontinence) with a combination of daily laxatives and behavior modification, rather than either therapy alone (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Laxative therapy
         </strong>
         – The choice of laxative is less important than using an adequate dose and assuring compliance. The dose should be based upon the child's age, body weight, and severity of constipation  (
         <a class="graphic graphic_table graphicRef63381" href="/z/d/graphic/63381.html" rel="external">
          table 2
         </a>
         ), titrated to achieve approximately one soft, normal-caliber stool daily. An example of a typical maintenance regimen is outlined in the table  (
         <a class="graphic graphic_table graphicRef61175" href="/z/d/graphic/61175.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Maintenance laxative therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         We suggest use of
         <a class="drug drug_pediatric" data-topicid="13070" href="/z/d/drug information/13070.html" rel="external">
          polyethylene glycol 3350
         </a>
         as the initial choice for maintenance therapy rather than other laxatives (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This drug is safe, effective, and usually better accepted by children than other laxatives. High doses of polyethylene glycol also may be effective for initial disimpaction of children with mild to moderate constipation. (See
         <a class="local">
          'Polyethylene glycol'
         </a>
         above and
         <a class="local">
          'Disimpaction (for select children)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Behavior therapy
         </strong>
         – Include a behavior modification plan to support regular toileting habits and encourage a child's cooperation. Components include toilet sitting after meals under the supervision and encouragement of a caregiver, proper positioning on the toilet  (
         <a class="graphic graphic_figure graphicRef119803" href="/z/d/graphic/119803.html" rel="external">
          figure 2
         </a>
         ), a reward system to enhance the child's cooperation, and keeping a record of stooling  (
         <a class="graphic graphic_figure graphicRef62849" href="/z/d/graphic/62849.html" rel="external">
          figure 3A
         </a>
         ). (See
         <a class="local">
          'Behavior modification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Rescue plan
         </strong>
         – Arrange a "rescue" plan if the child goes more than three days without passing stool or has other indications of recurrence (ie, hard stools, abdominal pain, smears in the underwear). The rescue plan may involve temporary escalation of the osmotic laxative dose or administration of a stimulant laxative, enema, or suppository. After successful rescue therapy, continue treatment with the maintenance osmotic laxative but at a higher dose. (See
         <a class="local">
          'Management of relapses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Follow up
         </strong>
         – Arrange regular and frequent follow-up to reinforce the need for continuation of laxative therapy, toilet sitting, and dietary changes. Titrate the laxative dose as needed and review the rescue plan. (See
         <a class="local">
          'Monitoring and follow-up'
         </a>
         above and
         <a class="local">
          'Management of relapses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tapering laxatives
         </strong>
         – Once the child has achieved regular bowel habits, reduce the frequency of toilet sitting and laxative use. We typically wait until optimal bowel habits are achieved and stable for at least six months before laxative use is further decreased. Some children require ongoing laxative treatment for one or more years. Maintaining behavioral and dietary interventions is particularly important as laxative therapy is discontinued. (See
         <a class="local">
          'Tapering laxative therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other specific interventions
         </strong>
         – Interventions that may be helpful for selected patients include biofeedback therapy, botulinum toxin injection, or various surgical interventions. (See
         <a class="local">
          'Specific interventions for selected patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonretentive fecal incontinence
         </strong>
         – Treatment of children with functional nonretentive fecal incontinence (fecal incontinence without evidence of constipation) includes similar behavioral interventions, without laxatives. This disorder is far less common and must be distinguished from constipation-associated fecal incontinence. Children with fecal incontinence should have a careful evaluation for underlying constipation, including a digital rectal examination, because constipation is not always recognized by the child or caregiver. (See
         <a class="local">
          'Treatment of nonretentive fecal incontinence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         <strong>
          ACKNOWLEDGMENT
         </strong>
         — The UpToDate editorial staff acknowledges George Ferry, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol 2006; 101:2401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robin SG, Keller C, Zwiener R, et al. Prevalence of Pediatric Functional Gastrointestinal Disorders Utilizing the Rome IV Criteria. J Pediatr 2018; 195:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steutel NF, Zeevenhooven J, Scarpato E, et al. Prevalence of Functional Gastrointestinal Disorders in European Infants and Toddlers. J Pediatr 2020; 221:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V. Prevalence, symptoms and outcome of constipation in infants and toddlers. J Pediatr 2005; 146:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benninga MA, Faure C, Hyman PE, et al. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyams JS, Di Lorenzo C, Saps M, et al. Functional Disorders: Children and Adolescents. Gastroenterology 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michail S, Gendy E, Preud'Homme D, Mezoff A. Polyethylene glycol for constipation in children younger than eighteen months old. J Pediatr Gastroenterol Nutr 2004; 39:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V, Krishna R, Pashankar DS. Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers. J Pediatr Gastroenterol Nutr 2004; 39:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy D, Akriche F, Amlani B, Shakir S. Utilisation and Safety of Polyethylene Glycol 3350 With Electrolytes in Children Under 2 Years: A Retrospective Cohort. J Pediatr Gastroenterol Nutr 2021; 72:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bekkali NLH, Hoekman DR, Liem O, et al. Polyethylene Glycol 3350 With Electrolytes Versus Polyethylene Glycol 4000 for Constipation: A Randomized, Controlled Trial. J Pediatr Gastroenterol Nutr 2018; 66:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilanova-Sanchez A, Gasior AC, Toocheck N, et al. Are Senna based laxatives safe when used as long term treatment for constipation in children? J Pediatr Surg 2018; 53:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schonwald A, Rappaport L. Consultation with the specialist: encopresis: assessment and management. Pediatr Rev 2004; 25:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abi-Hanna A, Lake AM. Constipation and encopresis in childhood. Pediatr Rev 1998; 19:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V. Chronic constipation in children. Gastroenterology 1993; 105:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felt B, Wise CG, Olson A, et al. Guideline for the management of pediatric idiopathic constipation and soiling. Multidisciplinary team from the University of Michigan Medical Center in Ann Arbor. Arch Pediatr Adolesc Med 1999; 153:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V. Clinical approach to fecal soiling in children. Clin Pediatr (Phila) 2000; 39:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brazzelli M, Griffiths PV, Cody JD, Tappin D. Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children. Cochrane Database Syst Rev 2011; :CD002240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V. Controversies in the management of chronic constipation. J Pediatr Gastroenterol Nutr 2001; 32 Suppl 1:S38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V. Encopresis. Curr Opin Pediatr 2002; 14:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youssef NN, Di Lorenzo C. Childhood constipation: evaluation and treatment. J Clin Gastroenterol 2001; 33:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staiano A, Andreotti MR, Greco L, et al. Long-term follow-up of children with chronic idiopathic constipation. Dig Dis Sci 1994; 39:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benninga MA, Taminiau JA. Diagnosis and treatment efficacy of functional non-retentive fecal soiling in childhood. J Pediatr Gastroenterol Nutr 2001; 32 Suppl 1:S42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Ginkel R, Reitsma JB, Büller HA, et al. Childhood constipation: longitudinal follow-up beyond puberty. Gastroenterology 2003; 125:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGrath ML, Mellon MW, Murphy L. Empirically supported treatments in pediatric psychology: constipation and encopresis. J Pediatr Psychol 2000; 25:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks RC, Copen RM, Cox DJ, et al. Review of the treatment literature for encopresis, functional constipation, and stool-toileting refusal. Ann Behav Med 2000; 22:260.
          </a>
         </li>
         <li class="breakAll">
          Rockney R. Encopresis. In: Developmental-Behavioral Pediatrics, 3rd ed, Levine MD, Carey WB, Crocker AC (Eds), WB Saunders, 1999. p.413.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine MD. Encopresis: its potentiation, evaluation, and alleviation. Pediatr Clin North Am 1982; 29:315.
          </a>
         </li>
         <li class="breakAll">
          Weissman L, Bridgemohan C. Bowel function, toileting, and encopresis. In: Developmental-Behavioral Pediatrics, 4th ed, Carey WB, Crocker AC, Coleman WL, et al (Eds), Saunders Elsevier, 2009. p.610.
         </li>
         <li class="breakAll">
          The poo in you. Educational video from the Children's Hospital of Colorado, sponsored by a grant from the NASPGHAN foundation. Available at: https://www.youtube.com/watch?v=SgBj7Mc_4sc (Accessed on November 10, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borowitz SM, Cox DJ, Kovatchev B, et al. Treatment of childhood constipation by primary care physicians: efficacy and predictors of outcome. Pediatrics 2005; 115:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gleghorn EE, Heyman MB, Rudolph CD. No-enema therapy for idiopathic constipation and encopresis. Clin Pediatr (Phila) 1991; 30:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alper A, Pashankar DS. Polyethylene glycol: a game-changer laxative for children. J Pediatr Gastroenterol Nutr 2013; 57:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bekkali NL, van den Berg MM, Dijkgraaf MG, et al. Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG. Pediatrics 2009; 124:e1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Youssef NN, Peters JM, Henderson W, et al. Dose response of PEG 3350 for the treatment of childhood fecal impaction. J Pediatr 2002; 141:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolia V, Lin CH, Elitsur Y. A prospective randomized study with mineral oil and oral lavage solution for treatment of faecal impaction in children. Aliment Pharmacol Ther 1993; 7:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke VA, Younoszai MK. Effect of treatment on rectal and sigmoid motility in chronically constipated children. Pediatrics 1984; 73:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffin GC, Roberts SD, Graham G. How to resolve stool retention in a child. Underwear soiling is not a behavior problem. Postgrad Med 1999; 105:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halabi IM. Cisapride in management of chronic pediatric constipation. J Pediatr Gastroenterol Nutr 1999; 28:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon M, MacDonald JK, Parker CE, et al. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database Syst Rev 2016; :CD009118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingebo KB, Heyman MB. Polyethylene glycol-electrolyte solution for intestinal clearance in children with refractory encopresis. A safe and effective therapeutic program. Am J Dis Child 1988; 142:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilger MA, Wagner ML, Barrish JO, et al. New treatment for rectal impaction in children: an efficacy, comfort, and safety trial of the pulsed-irrigation enhanced-evacuation procedure. J Pediatr Gastroenterol Nutr 1994; 18:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke MS, Ragi JM, Karamanoukian HL, et al. New strategies in nonoperative management of meconium ileus. J Pediatr Surg 2002; 37:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao SC, Franken EA Jr. Nonoperative treatment of simple meconium ileus: a survey of the Society for Pediatric Radiology. Pediatr Radiol 1995; 25:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood BP, Katzberg RW. Tween 80/diatrizoate enemas in bowel obstruction. AJR Am J Roentgenol 1978; 130:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helikson MA, Parham WA, Tobias JD. Hypocalcemia and hyperphosphatemia after phosphate enema use in a child. J Pediatr Surg 1997; 32:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biebl A, Grillenberger A, Schmitt K. Enema-induced severe hyperphosphatemia in children. Eur J Pediatr 2009; 168:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendoza J, Legido J, Rubio S, Gisbert JP. Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther 2007; 26:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ismail EA, Al-Mutairi G, Al-Anzy H. A fatal small dose of phosphate enema in a young child with no renal or gastrointestinal abnormality. J Pediatr Gastroenterol Nutr 2000; 30:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisman LE, Merenstein GB, Digirol M, et al. The effect of early meconium evacuation on early-onset hyperbilirubinemia. Am J Dis Child 1983; 137:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orchard JL, Lawson R. Severe colitis induced by soap enemas. South Med J 1986; 79:1459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pike BF, Phillippi PJ, Lawson EH Jr. Soap colitis. N Engl J Med 1971; 285:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ZISKIND A, GELLIS SS. Water intoxication following tap-water enemas. AMA J Dis Child 1958; 96:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chertow GM, Brady HR. Hyponatraemia from tap-water enema. Lancet 1994; 344:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker M, Warner BW, Brilli RJ, Jacobs BR. Cardiopulmonary compromise associated with milk and molasses enema use in children. J Pediatr Gastroenterol Nutr 2003; 36:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashton MR, Sutton D, Nielsen M. Severe magnesium toxicity after magnesium sulphate enema in a chronically constipated child. BMJ 1990; 300:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown AT, Campbell WA. Hazards of hypertonic magnesium enema therapy. Arch Dis Child 1978; 53:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tofil NM, Benner KW, Winkler MK. Fatal hypermagnesemia caused by an Epsom salt enema: a case illustration. South Med J 2005; 98:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koppen IJ, Di Lorenzo C. Do We Really Need Soap to Clean the Rectum? J Pediatr Gastroenterol Nutr 2016; 63:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonilla S, Nurko S, Rodriguez L. Long-term Use of Bisacodyl in Pediatric Functional Constipation Refractory to Conventional Therapy. J Pediatr Gastroenterol Nutr 2020; 71:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonring K, Dolan B, Kapke TL, et al. Group Treatment of Fecal Incontinence: A Description of an Interdisciplinary Intervention. J Pediatr Gastroenterol Nutr 2019; 69:e70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolan T, Debelle G, Oberklaid F, Coffey C. Randomised trial of laxatives in treatment of childhood encopresis. Lancet 1991; 338:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine MD, Bakow H. Children with encopresis: a study of treatment outcome. Pediatrics 1976; 58:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howe AC, Walker CE. Behavioral management of toilet training, enuresis, and encopresis. Pediatr Clin North Am 1992; 39:413.
          </a>
         </li>
         <li class="breakAll">
          Belamarich PF. Constipation. In: Primary Pediatric Care, 4th ed, Hoekelman RA (Ed), Mosby, 2001. p.1066.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolan T, Oberklaid F. New concepts in the management of encopresis. Pediatr Rev 1993; 14:447.
          </a>
         </li>
         <li class="breakAll">
          Croffie JMB, Fitzgerald JF. Idiopathic constipation. In: Pediatric Gastrointestinal Disease, 4th ed, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, 2004. p.1001.
         </li>
         <li class="breakAll">
          Loening-Baucke V. Constipation and encopresis. In: Pediatric Gastroenterology and Nutrition in Clinical Practice, Lifschitz CH (Ed), Marcel Dekker, 2001. p.551.
         </li>
         <li class="breakAll">
          Croffie JMB, Fitzgerald JF. Idiopathic constipation. In: Pediatric Gastrointestinal Disease, 4th ed, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, 2004. p.1002.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V, Miele E, Staiano A. Fiber (glucomannan) is beneficial in the treatment of childhood constipation. Pediatrics 2004; 113:e259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao HC, Lai MW, Kong MS, et al. Cutoff volume of dietary fiber to ameliorate constipation in children. J Pediatr 2008; 153:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabbers MM, Boluyt N, Berger MY, Benninga MA. Nonpharmacologic treatments for childhood constipation: systematic review. Pediatrics 2011; 128:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castillejo G, Bulló M, Anguera A, et al. A controlled, randomized, double-blind trial to evaluate the effect of a supplement of cocoa husk that is rich in dietary fiber on colonic transit in constipated pediatric patients. Pediatrics 2006; 118:e641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chmielewska A, Horvath A, Dziechciarz P, Szajewska H. Glucomannan is not effective for the treatment of functional constipation in children: a double-blind, placebo-controlled, randomized trial. Clin Nutr 2011; 30:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tappin D, Grzeda M, Joinson C, Heron J. Challenging the view that lack of fibre causes childhood constipation. Arch Dis Child 2020; 105:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young RJ, Beerman LE, Vanderhoof JA. Increasing oral fluids in chronic constipation in children. Gastroenterol Nurs 1998; 21:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irastorza I, Ibañez B, Delgado-Sanzonetti L, et al. Cow's-milk-free diet as a therapeutic option in childhood chronic constipation. J Pediatr Gastroenterol Nutr 2010; 51:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daher S, Tahan S, Solé D, et al. Cow's milk protein intolerance and chronic constipation in children. Pediatr Allergy Immunol 2001; 12:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iacono G, Cavataio F, Montalto G, et al. Intolerance of cow's milk and chronic constipation in children. N Engl J Med 1998; 339:1100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah N, Lindley K, Milla P. Cow's milk and chronic constipation in children. N Engl J Med 1999; 340:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroccio A, Montalto G, Custro N, et al. Evidence of very delayed clinical reactions to cow's milk in cow's milk-intolerant patients. Allergy 2000; 55:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKeown C, Hisle-Gorman E, Eide M, et al. Association of constipation and fecal incontinence with attention-deficit/hyperactivity disorder. Pediatrics 2013; 132:e1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovacic K, Sood MR, Mugie S, et al. A multicenter study on childhood constipation and fecal incontinence: effects on quality of life. J Pediatr 2015; 166:1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dijk M, Benninga MA, Grootenhuis MA, Last BF. Prevalence and associated clinical characteristics of behavior problems in constipated children. Pediatrics 2010; 125:e309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stark LJ, Owens-Stively J, Spirito A, et al. Group behavioral treatment of retentive encopresis. J Pediatr Psychol 1990; 15:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V. Biofeedback treatment for chronic constipation and encopresis in childhood: long-term outcome. Pediatrics 1995; 96:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Plas RN, Benninga MA, Büller HA, et al. Biofeedback training in treatment of childhood constipation: a randomised controlled study. Lancet 1996; 348:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Plas RN, Benninga MA, Redekop WK, et al. Randomised trial of biofeedback training for encopresis. Arch Dis Child 1996; 75:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halleran DR, Lu PL, Ahmad H, et al. Anal sphincter botulinum toxin injection in children with functional anorectal and colonic disorders: A large institutional study and review of the literature focusing on complications. J Pediatr Surg 2019; 54:2305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siminas S, Losty PD. Current Surgical Management of Pediatric Idiopathic Constipation: A Systematic Review of Published Studies. Ann Surg 2015; 262:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedmacher F, Puri P. Comparison of posterior internal anal sphincter myectomy and intrasphincteric botulinum toxin injection for treatment of internal anal sphincter achalasia: a meta-analysis. Pediatr Surg Int 2012; 28:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baaleman DF, Malamisura M, Benninga MA, et al. The not-so-rare absent RAIR: Internal anal sphincter achalasia in a review of 1072 children with constipation undergoing high-resolution anorectal manometry. Neurogastroenterol Motil 2021; 33:e14028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keshtgar AS, Ward HC, Sanei A, Clayden GS. Botulinum toxin, a new treatment modality for chronic idiopathic constipation in children: long-term follow-up of a double-blind randomized trial. J Pediatr Surg 2007; 42:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmadi J, Azary S, Ashjaei B, et al. Intrasphincteric botulinum toxin injection in treatment of chronic idiopathic constipation in children. Iran J Pediatr 2013; 23:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zar-Kessler C, Kuo B, Belkind-Gerson J. Botulinum toxin injection for childhood constipation is safe and can be effective regardless of anal sphincter dynamics. J Pediatr Surg 2018; 53:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radwan AB, Gadallah MA, Shahawy MR, et al. Can botulinum toxin help in managing children with functional constipation and obstructed defecation? J Pediatr Surg 2021; 56:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sulkowski JP, Nacion KM, Deans KJ, et al. Sacral nerve stimulation: a promising therapy for fecal and urinary incontinence and constipation in children. J Pediatr Surg 2015; 50:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trinidad S, Jensen A, Holder M, et al. Sacral Nerve Stimulation in Children with Medically Refractory Fecal Incontinence or Severe Constipation. J Pediatr Surg 2023; 58:1594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu PL, Koppen IJN, Orsagh-Yentis DK, et al. Sacral nerve stimulation for constipation and fecal incontinence in children: Long-term outcomes, patient benefit, and parent satisfaction. Neurogastroenterol Motil 2018; 30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velasco-Benitez C, Villamarin E, Mendez M, et al. Efficacy of transcutaneous posterior tibial nerve stimulation in functional constipation. Eur J Pediatr 2023; 182:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christison-Lagay ER, Rodriguez L, Kurtz M, et al. Antegrade colonic enemas and intestinal diversion are highly effective in the management of children with intractable constipation. J Pediatr Surg 2010; 45:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong AL, Kravarusic D, Wong SL. Impact of cecostomy and antegrade colonic enemas on management of fecal incontinence and constipation: ten years of experience in pediatric population. J Pediatr Surg 2008; 43:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqui AA, Fishman SJ, Bauer SB, Nurko S. Long-term follow-up of patients after antegrade continence enema procedure. J Pediatr Gastroenterol Nutr 2011; 52:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mugie SM, Machado RS, Mousa HM, et al. Ten-year experience using antegrade enemas in children. J Pediatr 2012; 161:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolejs SC, Smith JK Jr, Sheplock J, et al. Contemporary short- and long-term outcomes in patients with unremitting constipation and fecal incontinence treated with an antegrade continence enema. J Pediatr Surg 2017; 52:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brophy S, Brennan K, Woodgate E, et al. Comparing quality of life improvement after antegrade continence enema (ACE) therapy for patients with organic and functional constipation / encopresis. J Pediatr Surg 2022; 57:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villarreal J, Sood M, Zangen T, et al. Colonic diversion for intractable constipation in children: colonic manometry helps guide clinical decisions. J Pediatr Gastroenterol Nutr 2001; 33:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levitt MA, Peña A. Surgery and constipation: when, how, yes, or no? J Pediatr Gastroenterol Nutr 2005; 41 Suppl 1:S58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asipu D, Jaffray B. Treatment of severe childhood constipation with restorative proctocolectomy. Arch Dis Child 2010; 95:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keuzenkamp-Jansen CW, Fijnvandraat CJ, Kneepkens CM, Douwes AC. Diagnostic dilemmas and results of treatment for chronic constipation. Arch Dis Child 1996; 75:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrahamian FP, Lloyd-Still JD. Chronic constipation in childhood: a longitudinal study of 186 patients. J Pediatr Gastroenterol Nutr 1984; 3:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutphen JL, Borowitz SM, Hutchison RL, Cox DJ. Long-term follow-up of medically treated childhood constipation. Clin Pediatr (Phila) 1995; 34:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pijpers MA, Bongers ME, Benninga MA, Berger MY. Functional constipation in children: a systematic review on prognosis and predictive factors. J Pediatr Gastroenterol Nutr 2010; 50:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V. Factors determining outcome in children with chronic constipation and faecal soiling. Gut 1989; 30:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bongers ME, van Wijk MP, Reitsma JB, Benninga MA. Long-term prognosis for childhood constipation: clinical outcomes in adulthood. Pediatrics 2010; 126:e156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V. Polyethylene glycol without electrolytes for children with constipation and encopresis. J Pediatr Gastroenterol Nutr 2002; 34:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pashankar DS, Bishop WP. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. J Pediatr 2001; 139:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pashankar DS, Loening-Baucke V, Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med 2003; 157:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupont C, Leluyer B, Amar F, et al. A dose determination study of polyethylene glycol 4000 in constipated children: factors influencing the maintenance dose. J Pediatr Gastroenterol Nutr 2006; 42:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nurko S, Youssef NN, Sabri M, et al. PEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trial. J Pediatr 2008; 153:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dupont C, Leluyer B, Maamri N, et al. Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr 2005; 41:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams KC, Rogers LK, Hill I, et al. PEG 3350 Administration Is Not Associated with Sustained Elevation of Glycol Levels. J Pediatr 2018; 195:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuizenga-Wessel S, Di Lorenzo C, Nicholson LM, et al. Screening for autism identifies behavioral disorders in children functional defecation disorders. Eur J Pediatr 2016; 175:1371.
          </a>
         </li>
         <li class="breakAll">
          North American Society For Pediatric Gastroenterology, Hepatology &amp; Nutrition. Polyethylene Glycol 3350 (PEG 3350) Frequently Asked Questions. 2015. Available at: http://naspghn.informz.net/NASPGHN/data/images/PEG%203350%20FAQ.pdf (Accessed on January 23, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Candy DC, Edwards D, Geraint M. Treatment of faecal impaction with polyethelene glycol plus electrolytes (PGE + E) followed by a double-blind comparison of PEG + E versus lactulose as maintenance therapy. J Pediatr Gastroenterol Nutr 2006; 43:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loening-Baucke V, Pashankar DS. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics 2006; 118:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treepongkaruna S, Simakachorn N, Pienvichit P, et al. A randomised, double-blind study of polyethylene glycol 4000 and lactulose in the treatment of constipation in children. BMC Pediatr 2014; 14:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarzebicka D, Sieczkowska-Golub J, Kierkus J, et al. PEG 3350 Versus Lactulose for Treatment of Functional Constipation in Children: Randomized Study. J Pediatr Gastroenterol Nutr 2019; 68:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voskuijl W, de Lorijn F, Verwijs W, et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut 2004; 53:1590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanetti G, Marchiori E, Gasparetto TD, et al. Lipoid pneumonia in children following aspiration of mineral oil used in the treatment of constipation: high-resolution CT findings in 17 patients. Pediatr Radiol 2007; 37:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bandla HP, Davis SH, Hopkins NE. Lipoid pneumonia: a silent complication of mineral oil aspiration. Pediatrics 1999; 103:E19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DAVIDSON M, KUGLER MM, BAUER CH. Diagnosis and management in children with severe and protracted constipation and obstipation. J Pediatr 1963; 62:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark JH, Russell GJ, Fitzgerald JF, Nagamori KE. Serum beta-carotene, retinol, and alpha-tocopherol levels during mineral oil therapy for constipation. Am J Dis Child 1987; 141:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sondheimer JM, Gervaise EP. Lubricant versus laxative in the treatment of chronic functional constipation of children: a comparative study. J Pediatr Gastroenterol Nutr 1982; 1:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan JE, Berman BW. The pediatric forum: hypermagnesemia with lethargy and hypotonia due to administration of magnesium hydroxide to a 4-week-old infant. Arch Pediatr Adolesc Med 2000; 154:1272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mofenson HC, Caraccio TR. Magnesium intoxication in a neonate from oral magnesium hydroxide laxative. J Toxicol Clin Toxicol 1991; 29:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alison LH, Bulugahapitiya D. Laxative induced magnesium poisoning in a 6 week old infant. BMJ 1990; 300:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humphrey M, Kennon S, Pramanik AK. Hypermagnesemia from antacid administration in a newborn infant. J Pediatr 1981; 98:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price KJ, Elliott TM. What is the role of stimulant laxatives in the management of childhood constipation and soiling?. Cochrane Database Syst Rev 2001; :CD002040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003; 349:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos-Jasso KA, Arredondo-García JL, Maza-Vallejos J, Lezama-Del Valle P. Effectiveness of senna vs polyethylene glycol as laxative therapy in children with constipation related to anorectal malformation. J Pediatr Surg 2017; 52:84.
          </a>
         </li>
         <li class="breakAll">
          Manufacturer's prescribing information for LINZESS (linaclotide), June 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202811s021lbl.pdf (Accessed on June 13, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linaclotide (Linzess) for functional constipation. Med Lett Drugs Ther 2023; 65:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benninga MA, Hussain SZ, Sood MR, et al. Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension. Clin Gastroenterol Hepatol 2022; 20:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mugie SM, Korczowski B, Bodi P, et al. Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology 2014; 147:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nurko S, Saps M. Treating constipation with prucalopride: one size does not fit all. Gastroenterology 2014; 147:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wojtyniak K, Szajewska H. Systematic review: probiotics for functional constipation in children. Eur J Pediatr 2017; 176:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris RG, Neale EP, Ferreira I. When poorly conducted systematic reviews and meta-analyses can mislead: a critical appraisal and update of systematic reviews and meta-analyses examining the effects of probiotics in the treatment of functional constipation in children. Am J Clin Nutr 2019; 110:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace C, Sinopoulou V, Gordon M, et al. Probiotics for treatment of chronic constipation in children. Cochrane Database Syst Rev 2022; 3:CD014257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoppi G, Cinquetti M, Luciano A, et al. The intestinal ecosystem in chronic functional constipation. Acta Paediatr 1998; 87:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009; 29:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr 2010; 157:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saneian H, Tavakkol K, Adhamian P, Gholamrezaei A. Comparison of Lactobacillus Sporogenes plus mineral oil and mineral oil alone in the treatment of childhood functional constipation. J Res Med Sci 2013; 18:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Indrio F, Di Mauro A, Riezzo G, et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. JAMA Pediatr 2014; 168:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banaszkiewicz A, Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr 2005; 146:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wojtyniak K, Horvath A, Dziechciarz P, Szajewska H. Lactobacillus casei rhamnosus Lcr35 in the Management of Functional Constipation in Children: A Randomized Trial. J Pediatr 2017; 184:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Ginkel R, Benninga MA, Blommaart PJ, et al. Lack of benefit of laxatives as adjunctive therapy for functional nonretentive fecal soiling in children. J Pediatr 2000; 137:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burgers R, Reitsma JB, Bongers ME, et al. Functional nonretentive fecal incontinence: do enemas help? J Pediatr 2013; 162:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voskuijl WP, Reitsma JB, van Ginkel R, et al. Longitudinal follow-up of children with functional nonretentive fecal incontinence. Clin Gastroenterol Hepatol 2006; 4:67.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5873 Version 69.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17032205" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Epidemiology of childhood constipation: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29398057" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence of Pediatric Functional Gastrointestinal Disorders Utilizing the Rome IV Criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32446468" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prevalence of Functional Gastrointestinal Disorders in European Infants and Toddlers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15756220" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prevalence, symptoms and outcome of constipation in infants and toddlers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27144631" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Childhood Functional Gastrointestinal Disorders: Neonate/Toddler.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27144632" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Functional Disorders: Children and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24345831" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15269628" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Polyethylene glycol for constipation in children younger than eighteen months old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15572895" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33587408" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Utilisation and Safety of Polyethylene Glycol 3350 With Electrolytes in Children Under 2 Years: A Retrospective Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28906317" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Polyethylene Glycol 3350 With Electrolytes Versus Polyethylene Glycol 4000 for Constipation: A Randomized, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29429768" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Are Senna based laxatives safe when used as long term treatment for constipation in children?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15286273" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Consultation with the specialist: encopresis: assessment and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9439166" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Constipation and encopresis in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8224663" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Chronic constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10201721" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Guideline for the management of pediatric idiopathic constipation and soiling. Multidisciplinary team from the University of Michigan Medical Center in Ann Arbor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11063041" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinical approach to fecal soiling in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22161370" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11321420" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Controversies in the management of chronic constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12352250" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11500607" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Childhood constipation: evaluation and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8131693" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Long-term follow-up of children with chronic idiopathic constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11321422" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Diagnosis and treatment efficacy of functional non-retentive fecal soiling in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12891536" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Childhood constipation: longitudinal follow-up beyond puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10814690" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Empirically supported treatments in pediatric psychology: constipation and encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11211851" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Review of the treatment literature for encopresis, functional constipation, and stool-toileting refusal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11211851" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Review of the treatment literature for encopresis, functional constipation, and stool-toileting refusal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7070866" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Encopresis: its potentiation, evaluation, and alleviation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7070866" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Encopresis: its potentiation, evaluation, and alleviation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7070866" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Encopresis: its potentiation, evaluation, and alleviation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15805358" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Treatment of childhood constipation by primary care physicians: efficacy and predictors of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1764874" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : No-enema therapy for idiopathic constipation and encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23591910" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Polyethylene glycol: a game-changer laxative for children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19948614" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12219064" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Dose response of PEG 3350 for the treatment of childhood fecal impaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8280820" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A prospective randomized study with mineral oil and oral lavage solution for treatment of faecal impaction in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6694877" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effect of treatment on rectal and sigmoid motility in chronically constipated children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9924501" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : How to resolve stool retention in a child. Underwear soiling is not a behavior problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9932855" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cisapride in management of chronic pediatric constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27531591" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Osmotic and stimulant laxatives for the management of childhood constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3344724" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Polyethylene glycol-electrolyte solution for intestinal clearance in children with refractory encopresis. A safe and effective therapeutic program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8126626" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : New treatment for rectal impaction in children: an efficacy, comfort, and safety trial of the pulsed-irrigation enhanced-evacuation procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11987095" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : New strategies in nonoperative management of meconium ileus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7596674" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Nonoperative treatment of simple meconium ileus: a survey of the Society for Pediatric Radiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/416689" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Tween 80/diatrizoate enemas in bowel obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9269980" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Hypocalcemia and hyperphosphatemia after phosphate enema use in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18408952" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Enema-induced severe hyperphosphatemia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17555417" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Systematic review: the adverse effects of sodium phosphate enema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10697146" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A fatal small dose of phosphate enema in a young child with no renal or gastrointestinal abnormality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6858980" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The effect of early meconium evacuation on early-onset hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3775481" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Severe colitis induced by soap enemas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5087724" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Soap colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13594017" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Water intoxication following tap-water enemas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7915790" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Hyponatraemia from tap-water enema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12500012" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Cardiopulmonary compromise associated with milk and molasses enema use in children
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2107950" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Severe magnesium toxicity after magnesium sulphate enema in a chronically constipated child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/727823" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Hazards of hypertonic magnesium enema therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15759964" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Fatal hypermagnesemia caused by an Epsom salt enema: a case illustration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26859088" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Do We Really Need Soap to Clean the Rectum?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15654804" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Myths and misconceptions about chronic constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32459741" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Long-term Use of Bisacodyl in Pediatric Functional Constipation Refractory to Conventional Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31058779" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Group Treatment of Fecal Incontinence: A Description of an Interdisciplinary Intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1678797" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Randomised trial of laxatives in treatment of childhood encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/995511" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Children with encopresis: a study of treatment outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1574352" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Behavioral management of toilet training, enuresis, and encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1574352" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Behavioral management of toilet training, enuresis, and encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8284284" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : New concepts in the management of encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8284284" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : New concepts in the management of encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8284284" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : New concepts in the management of encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8284284" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : New concepts in the management of encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14993586" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Fiber (glucomannan) is beneficial in the treatment of childhood constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18571534" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cutoff volume of dietary fiber to ameliorate constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21949142" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Nonpharmacologic treatments for childhood constipation: systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16950955" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A controlled, randomized, double-blind trial to evaluate the effect of a supplement of cocoa husk that is rich in dietary fiber on colonic transit in constipated pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21320737" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Glucomannan is not effective for the treatment of functional constipation in children: a double-blind, placebo-controlled, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32156695" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Challenging the view that lack of fibre causes childhood constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9849179" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Increasing oral fluids in chronic constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20453672" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Cow's-milk-free diet as a therapeutic option in childhood chronic constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11846872" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Cow's milk protein intolerance and chronic constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9770556" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Intolerance of cow's milk and chronic constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10084907" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Cow's milk and chronic constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10858991" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Evidence of very delayed clinical reactions to cow's milk in cow's milk-intolerant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24144702" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Association of constipation and fecal incontinence with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26008173" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A multicenter study on childhood constipation and fecal incontinence: effects on quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20083527" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Prevalence and associated clinical characteristics of behavior problems in constipated children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2283574" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Group behavioral treatment of retentive encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7596696" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Biofeedback treatment for chronic constipation and encopresis in childhood: long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8813983" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Biofeedback training in treatment of childhood constipation: a randomised controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8957948" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Randomised trial of biofeedback training for encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31060739" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Anal sphincter botulinum toxin injection in children with functional anorectal and colonic disorders: A large institutional study and review of the literature focusing on complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25775070" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Current Surgical Management of Pediatric Idiopathic Constipation: A Systematic Review of Published Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22806601" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Comparison of posterior internal anal sphincter myectomy and intrasphincteric botulinum toxin injection for treatment of internal anal sphincter achalasia: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33301220" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The not-so-rare absent RAIR: Internal anal sphincter achalasia in a review of 1072 children with constipation undergoing high-resolution anorectal manometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17448764" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Botulinum toxin, a new treatment modality for chronic idiopathic constipation in children: long-term follow-up of a double-blind randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24800020" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Intrasphincteric botulinum toxin injection in treatment of chronic idiopathic constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29395154" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Botulinum toxin injection for childhood constipation is safe and can be effective regardless of anal sphincter dynamics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32739102" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Can botulinum toxin help in managing children with functional constipation and obstructed defecation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25858097" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Sacral nerve stimulation: a promising therapy for fecal and urinary incontinence and constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37221127" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Sacral Nerve Stimulation in Children with Medically Refractory Fecal Incontinence or Severe Constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28799195" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Sacral nerve stimulation for constipation and fecal incontinence in children: Long-term outcomes, patient benefit, and parent satisfaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36637541" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Efficacy of transcutaneous posterior tibial nerve stimulation in functional constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20105606" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Antegrade colonic enemas and intestinal diversion are highly effective in the management of children with intractable constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18675633" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Impact of cecostomy and antegrade colonic enemas on management of fecal incontinence and constipation: ten years of experience in pediatric population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21502828" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Long-term follow-up of patients after antegrade continence enema procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22683036" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Ten-year experience using antegrade enemas in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27817835" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Contemporary short- and long-term outcomes in patients with unremitting constipation and fecal incontinence treated with an antegrade continence enema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35115169" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Comparing quality of life improvement after antegrade continence enema (ACE) therapy for patients with organic and functional constipation / encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11740234" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Colonic diversion for intractable constipation in children: colonic manometry helps guide clinical decisions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16131973" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Surgery and constipation: when, how, yes, or no?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20371582" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Treatment of severe childhood constipation with restorative proctocolectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8813868" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Diagnostic dilemmas and results of treatment for chronic constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6737192" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Chronic constipation in childhood: a longitudinal study of 186 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8565387" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Long-term follow-up of medically treated childhood constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20118805" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Functional constipation in children: a systematic review on prognosis and predictive factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2759495" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Factors determining outcome in children with chronic constipation and faecal soiling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20530072" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Long-term prognosis for childhood constipation: clinical outcomes in adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11930092" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Polyethylene glycol without electrolytes for children with constipation and encopresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11562624" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12860787" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16456412" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : A dose determination study of polyethylene glycol 4000 in constipated children: factors influencing the maintenance dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18534221" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : PEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16254521" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29395181" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : PEG 3350 Administration Is Not Associated with Sustained Elevation of Glycol Levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27624626" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Screening for autism identifies behavioral disorders in children functional defecation disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27624626" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Screening for autism identifies behavioral disorders in children functional defecation disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16819379" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Treatment of faecal impaction with polyethelene glycol plus electrolytes (PGE + E) followed by a double-blind comparison of PEG + E versus lactulose as maintenance therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16882804" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24943105" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : A randomised, double-blind study of polyethylene glycol 4000 and lactulose in the treatment of constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30383579" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : PEG 3350 Versus Lactulose for Treatment of Functional Constipation in Children: Randomized Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15479678" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17876572" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Lipoid pneumonia in children following aspiration of mineral oil used in the treatment of constipation: high-resolution CT findings in 17 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9925865" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Lipoid pneumonia: a silent complication of mineral oil aspiration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14025378" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Diagnosis and management in children with severe and protracted constipation and obstipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3673974" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Serum beta-carotene, retinol, and alpha-tocopherol levels during mineral oil therapy for constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6310075" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Lubricant versus laxative in the treatment of chronic functional constipation of children: a comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11115318" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : The pediatric forum: hypermagnesemia with lethargy and hypotonia due to administration of magnesium hydroxide to a 4-week-old infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2051509" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Magnesium intoxication in a neonate from oral magnesium hydroxide laxative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2105768" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Laxative induced magnesium poisoning in a 6 week old infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6970259" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Hypermagnesemia from antacid administration in a newborn infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11687009" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : What is the role of stimulant laxatives in the management of childhood constipation and soiling?.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14523145" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Chronic constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27836356" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Effectiveness of senna vs polyethylene glycol as laxative therapy in children with constipation related to anorectal malformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27836356" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Effectiveness of senna vs polyethylene glycol as laxative therapy in children with constipation related to anorectal malformation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37651297" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Linaclotide (Linzess) for functional constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33838349" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25239590" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Prucalopride is no more effective than placebo for children with functional constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25457845" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Treating constipation with prucalopride: one size does not fit all.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28762070" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Systematic review: probiotics for functional constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31127810" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : When poorly conducted systematic reviews and meta-analyses can mislead: a critical appraisal and update of systematic reviews and meta-analyses examining the effects of probiotics in the treatment of functional constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35349168" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Probiotics for treatment of chronic constipation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9736230" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : The intestinal ecosystem in chronic functional constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18801055" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20542295" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23914206" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Comparison of Lactobacillus Sporogenes plus mineral oil and mineral oil alone in the treatment of childhood functional constipation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24424513" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15756221" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28284477" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Lactobacillus casei rhamnosus Lcr35 in the Management of Functional Constipation in Children: A Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11113837" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Lack of benefit of laxatives as adjunctive therapy for functional nonretentive fecal soiling in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23164309" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Functional nonretentive fecal incontinence: do enemas help?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16431307" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Longitudinal follow-up of children with functional nonretentive fecal incontinence.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
